var title_f34_41_35472="CT-OctreoScan panc NET and liver mets";
var content_f34_41_35472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F85671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F85671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    CT/OctreoScan fusion demonstrating pancreatic neuroendocrine tumor (arrow) with radiotracer-avid liver metastases (arrowheads)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Jonathan R Strosberg.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35472=[""].join("\n");
var outline_f34_41_35472=null;
var title_f34_41_35473="Brivudine: International drug information";
var content_f34_41_35473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brivudine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Helpin (CZ, DE);",
"     </li>",
"     <li>",
"      Zostex (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of herpes zoster and herpes simplex",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 125 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 125 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10539 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35473=[""].join("\n");
var outline_f34_41_35473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303343\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977977\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977980\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977976\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821223\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977979\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35474="Noncontact map fascicular tachy";
var content_f34_41_35474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Noncontact endocardial map of fascicular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During tachycardia, the fascicular activation sequence is altered; panel A shows that activation begins near the left ventricular apex (red arrow) and panel B shows that activation (red arrow) propagates toward His bundle (white arrow) This rapid retrograde fascicular activation is closely followed by ventricular activation, seen as a white area in panel C. The relative delay in right ventricular activation produces a QRS complex with right bundle-branch block pattern in ECG lead I.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Peters NS, Jackman WM, Schilling RJ, et al. Circulation 1997; 95:1658.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35474=[""].join("\n");
var outline_f34_41_35474=null;
var title_f34_41_35475="Observations chart malaria";
var content_f34_41_35475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Observations chart malaria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        Observations chart",
"       </td>",
"       <td class=\"subtitle1_left\" colspan=\"25\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Day:",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Date:",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Day:",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Time",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        8a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        10a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        12a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        8p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        10p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        12m",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        8a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        10a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        12a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        8p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        10p",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        12m",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2a",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other times (cross out above line)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hours since admission",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Convulsions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Coma score:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Motor",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Verbal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eye",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Coma score total",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Vomiting/diarrhoea:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Drinking/feeding:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dehydration (0, +, ++)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Pallor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Cyanosis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Passing urine:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Pulse rate/min",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Respiratory rate/min",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Blood pressure - systolic/diastolic",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Temperature:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"6\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        39",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        38",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        37",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        36",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Temperature recorded (axillary/rectal)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Y/N (litres/min)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Oxygen saturation (without O2)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Blood:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"26\">",
"        Lab results:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPs (+, ++, +++, ++++, +++++)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Observer's initials",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Terrie Taylor, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35475=[""].join("\n");
var outline_f34_41_35475=null;
var title_f34_41_35476="Topical cocaine: Pediatric drug information";
var content_f34_41_35476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical cocaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=see_link\">",
"    see \"Topical cocaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/38/32355?source=see_link\">",
"    see \"Topical cocaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=see_link\">",
"      see \"Topical cocaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical application (ear, nose, throat, bronchoscopy): Concentrations of 1% to 4% are used; use lowest effective dose; do not exceed 1 mg/kg; patient tolerance, anesthetic technique, vascularity of tissue, and area to be anesthetized will determine dose needed. Solutions &gt;4% are not recommended due to increased risk and severity of systemic toxicities.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as hydrochloride: USP: 100% (5 g, 25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride: 4% (4 mL, 10 mL); 10% (4 mL, 10 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F154125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Use only on mucous membranes of the oral, laryngeal, and nasal cavities; do not use on extensive areas of broken skin; do not apply commercially available products to the eye (an extemporaneously prepared ophthalmic product must be made)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in well closed, light-resistant containers",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical anesthesia for mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (ventricular), cardiac arrhythmia, cardiomyopathy, cerebral vasculitis, CHF, decreased heart rate (low doses), fibrillation (atrial), flutter (atrial), hypertension, myocarditis, pulmonary hypertension, QRS prolongation, Raynaud's phenomenon, sinus bradycardia, sinus tachycardia, tachycardia (moderate doses) tachycardia (supraventricular), thrombosis, vasoconstriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, cerebral vascular accident, clonic-tonic reactions, CNS stimulation, dystonic reactions, euphoria, excitation, fever, hallucinations, headache, hyperthermia, nervousness, paranoia, psychosis, restlessness, seizure, slurred speech, sympathetic storm, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Madarosis, pruritus, skin infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, colonic ischemia, loss of taste perception, nausea, spontaneous bowel perforation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Priapism, uterine rupture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea (extrapyramidal), fasciculations, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Chemosis, iritis, Mydriasis (peak effect at 45 minutes; may last up to 12 hours), sloughing of the corneal epithelium, ulceration of the cornea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Myoglobinuria, necrotizing vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchiolitis obliterans organizing pneumonia, hyposmia, nasal congestion, nasal mucosa damage (when snorting), rhinitis, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Loss of smell, &ldquo;washed-out&rdquo; syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cocaine or any component; systemic use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypertension, severe cardiovascular disease, thyrotoxicosis, and in infants; use with caution in patients with severely traumatized mucosa in the region of intended application",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Cocaine may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Cocaine may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this product. Cocaine rapidly crosses the placenta in concentrations equal to those in the mother. Adverse events occur in the fetus (eg, congenital malformations, growth restriction), infant (neonatal abstinence syndrome), and mother (eg, preterm labor, placental abruption) following maternal abuse (Fajemirokun-Odudeyi, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, respiratory rate, temperature",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This results in inhibition of depolarization with resultant blockade of conduction; interferes with the uptake of norepinephrine by adrenergic nerve terminals producing vasoconstriction.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following topical administration to mucosa:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;30 minutes, depending upon route and dosage administered",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed through mucous membranes; absorption is limited by drug-induced vasoconstriction and enhanced by inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &sim;2 L/kg; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver; major metabolites are ecgonine methyl ester and benzoyl ecgonine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 75 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in urine as metabolites and unchanged drug (&lt;10%); cocaine metabolites may appear in the urine of neonates for up to 5 days after birth due to maternal cocaine use shortly before birth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Repeated ophthalmic applications to the eye may cause cornea to become clouded or pitted, therefore, NS should be used to irrigate and protect cornea during surgery; not for injection; cocaine intoxication of infants who are receiving breast milk from their mothers abusing cocaine has been reported",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chasnoff IJ, Lewis DE, and Squires L, &ldquo;Cocaine Intoxication in Breast-Fed Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1987, 80(6):836-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35476/abstract-text/3684393/pubmed\" id=\"3684393\" target=\"_blank\">",
"        3684393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenglass EJ, &ldquo;The Adverse Effects of Cocaine on the Developing Human,&rdquo; Yaffe SJ and Arana JV, eds,",
"      <i>",
"       Pediatric Pharmacology: Therapeutic Principles in Practice",
"      </i>",
"      , 2nd ed, Philadelphia, PA: WB Saunders Co, 1992, 598-604.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13177 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35476=[""].join("\n");
var outline_f34_41_35476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051861\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051855\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154089\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154073\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154125\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051866\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051858\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051865\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154130\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051870\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051854\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154119\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154084\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862039\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051860\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051868\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051869\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051871\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=related_link\">",
"      Topical cocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/38/32355?source=related_link\">",
"      Topical cocaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35477="Exanthematous drug eruption dark skin";
var content_f34_41_35477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Exanthematous (morbilliform) drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous small, discrete papules on the back of a patient with exanthematous drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35477=[""].join("\n");
var outline_f34_41_35477=null;
var title_f34_41_35478="Overview of the management of the severely burned patient";
var content_f34_41_35478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of the severely burned patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Gerd G Gauglitz, MMS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Felicia N Williams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35478/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/41/35478/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2965687942\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite major advances in therapeutic strategies for the management of patients with severe burns, including improved resuscitation, enhanced wound coverage, infection control, and management of inhalation injuries, the consequences of a severe burn are profound and result in complex metabolic changes that can adversely affect every organ system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Management of a patient with a severe burn injury is a long-term process that addresses the local burn wound as well as the systemic, psychologic, and social consequences of the injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5673403\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe (major) burn as defined by the American Burn Association burn injury severity grading system includes (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"mobipreview.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      25 percent total body surface area (TBSA) or greater, 10 to 40 years of age (excludes superficial burns, such as sun burn)",
"     </li>",
"     <li>",
"      20 percent TBSA or greater in children under 10 years and adults over 40 years of age (excludes superficial burns), 10 percent TBSA or greater full-thickness burns",
"     </li>",
"     <li>",
"      All burns involving eyes, ears, face, hands, feet, or perineum that are likely to result in cosmetic or functional impairment",
"     </li>",
"     <li>",
"      All high-voltage electrical burns",
"     </li>",
"     <li>",
"      All burn injuries complicated by major trauma or inhalation injury (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32070?source=see_link\">",
"       \"Overview and management strategies for the combined burn trauma patient\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      All patients with burn injuries and serious comorbidities (excludes superficial burns)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Classification and types of burns are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14168772\">",
"    <span class=\"h1\">",
"     EMERGENCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency management of the severely burned patient can be provided in the emergency department or in the intensive care unit (ICU), depending upon the protocol of the institution. In both scenarios, emergency management follows the principles of the Advanced Trauma Life Support Guidelines for assessment and stabilization of airway, breathing, circulation, disability, exposure, and environment control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/5\">",
"     5",
"    </a>",
"    ]. Primary and secondary assessments for the severity (partial- or full-thickness) and extent (total body surface area) of the burn and an evaluation for associated life-threatening injuries are performed promptly upon admission.",
"   </p>",
"   <p>",
"    Emergent management of the burn patient is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32070?source=see_link\">",
"     \"Overview and management strategies for the combined burn trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14168468\">",
"    <span class=\"h1\">",
"     TRIAGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;If emergent management is not provided at a designated burn center, patients with any of the following criteria should be transferred to a burn center as soon as stabilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial-thickness burns more than 10 percent of the total body surface area (TBSA).",
"     </li>",
"     <li>",
"      Burns involving the face, hands, feet, genitalia, perineum,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      major joints.",
"     </li>",
"     <li>",
"      Any full-thickness burn.",
"     </li>",
"     <li>",
"      Electrical burns, including lightning injury.",
"     </li>",
"     <li>",
"      Chemical burns.",
"     </li>",
"     <li>",
"      Inhalation injury.",
"     </li>",
"     <li>",
"      Pre-existing medical disorders that can complicate management, prolong recovery, or adversely affect outcome.",
"     </li>",
"     <li>",
"      Concomitant burns and trauma (eg, fractures) in which the burn injury poses the greater immediate risk of morbidity and mortality. If the trauma poses the greater immediate risk, the patient may be initially stabilized in a trauma center before being transferred to a burn unit. Physician judgment is necessary in these cases and should be in conjunction with the regional medical control plan and triage protocols. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32070?source=see_link\">",
"       \"Overview and management strategies for the combined burn trauma patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23977?source=see_link\">",
"       \"Management principles for burns resulting from mass disasters and war casualties\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Special requirements, such as social, emotional, or long-term rehabilitative needs.",
"     </li>",
"     <li>",
"      Children who require qualified pediatric personnel and equipment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If transportation is not feasible, or if no burn center is available, the patient is admitted to an intensive care unit (ICU) for acute management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1607614\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT IN THE ICU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute management in the ICU includes continuation of respiratory support, fluid resuscitation, cardiovascular stabilization, pain control, and local management of burn wounds initiated in the emergency department. The goal of the ICU care is to maintain end-organ perfusion and prevent burn shock. Fluid resuscitation with intravenous crystalloid solution is adjusted to maintain urine output at 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/hr",
"    </span>",
"    for adults and 1",
"    <span class=\"nowrap\">",
"     mL/kg/hr",
"    </span>",
"    for children. The effectiveness of perfusion is monitored using a central venous catheter, cardiac output monitor, and urinary catheter for the severely burned patient. A nasogastric tube is placed for gastric decompression. Once stabilized, the next set of priorities includes pain control, prevention of deep venous thrombosis and pulmonary emboli, early excision and tissue coverage (eg, skin grafts, myocutaneous flaps) of the burns, nutritional support, control of hypermetabolism, and prevention of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Pain control",
"    </strong>",
"    &mdash; Burns can be extremely painful, and management of burn pain is a priority (",
"    <a class=\"graphic graphic_table graphicRef59472 \" href=\"mobipreview.htm?17/54/18285\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76614 \" href=\"mobipreview.htm?29/50/30508\">",
"     table 3",
"    </a>",
"    ). The principles and treatment approaches for burn pain are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34169?source=see_link\">",
"       \"Burn pain: Principles of pharmacologic and nonpharmacologic management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38695?source=see_link\">",
"       \"Paradigm-based treatment approaches for burn pain control\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Thromboembolic event prophylaxis",
"    </strong>",
"    &mdash; Burn patients are at increased risk for thromboembolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/7\">",
"     7",
"    </a>",
"    ]. Prophylaxis is initiated upon admission to the ICU and includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      (LovenoxR) 40 mg subcutaneous daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      30 mg subcutaneous daily for patients weighing &lt;40 kg or with creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      40 mg subcutaneous twice daily for patients weighing &gt;100 kg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      30 mg twice daily for patients with associated lower extremity or pelvic orthopedic injuries or burns",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      5000 units subcutaneous every eight hours is used for patients who are not candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , such as patients with renal impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevention of deep vein thromboembolic events is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Wound management",
"    </strong>",
"    &mdash; Burn wound debridement, excision, and coverage is performed in the operating room, generally between 6 and 24 hours after the injury. Local burn wound treatment is reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20346?source=see_link\">",
"       \"Principles of burn reconstruction: Overview of surgical procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18409?source=see_link\">",
"       \"Primary operative management of hand burns\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Nutritional support",
"    </strong>",
"    &mdash; Nasoduodenal tubes are placed upon admission for early enteral nutrition. Enteral nutrition is typically initiated within the first 6 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/10\">",
"     10",
"    </a>",
"    ]. The following topics discuss nutritional support in the burn patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4215?source=see_link\">",
"       \"Overview of nutritional support for moderate to severe burn patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15716?source=see_link\">",
"       \"Evaluating nutritional support for moderate to severe burn patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11401?source=see_link\">",
"       \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Hypermetabolism",
"    </strong>",
"    &mdash; The metabolic rate increases proportionally to the increase in burn size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/11\">",
"     11",
"    </a>",
"    ]. The hypermetabolic response in burn patients is characterized by a hyperdynamic circulatory response with massive protein and lipid catabolism, total body protein loss, muscle wasting, peripheral insulin resistance, increased energy expenditure, increased body temperature, increased infection risks, and stimulated synthesis of acute phase proteins located in the liver and intestinal mucosa. The management of the hypermetabolic response is reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22330?source=see_link\">",
"       \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Infection",
"    </strong>",
"    &mdash; ICU management of severe burn patients can be complicated by burn wound infections. Patients are at a high risk of developing an invasive burn wound infection, also referred to as burn wound sepsis, which often leads to multi-organ dysfunction and death. Nosocomial infections (eg, central venous catheter source) and emerging multi-drug-resistant strains of bacteria and fungi contribute to burn wound infections, sepsis, and associated death. Recognition and treatment of burn wound sepsis is reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21417?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of burn wound sepsis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1469902\">",
"    <span class=\"h1\">",
"     INPATIENT NONACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be discharged from the ICU to the rehabilitation facility (or hospital ward when no such facility exists) when continuous cardiopulmonary monitoring is no longer required, although severely burned patients remain hypermetabolic for years. On average, patients remain in the ICU for one-half to one full day per percent total body surface (TBSA) burned (eg, a patient with an 80 percent TBSA burn will remain in the ICU for 40 to 80 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/12\">",
"     12",
"    </a>",
"    ]. Typically, at the time of transfer to the hospital ward, burn wounds are mostly healed, and most patients are tolerating full enteric nutrition and have started rehabilitation.",
"   </p>",
"   <p>",
"    Basic management includes daily dressing changes and once to twice daily rehabilitation sessions. Patients are weaned from continuous nutrition supplementation and are tolerating diets that meet their full nutritional requirement. Unless major complications occur, patients typically receive inpatient care for one to four weeks after discharge from the ICU, and depending upon their functional needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria to discharge patients from the ICU to the rehabilitation facility include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Closed wounds without significant functional imparities from burn wound contractures",
"     </li>",
"     <li>",
"      Patient is receiving and tolerating full enteral nutritional requirements",
"     </li>",
"     <li>",
"      Patient is functionally independent from a rehabilitative standpoint",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there are no functional disabilities from the burn injury, patients are discharged home without going to a rehabilitation facility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1469926\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term management of burn patients requires a team effort for months to years after the burn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/15\">",
"     15",
"    </a>",
"    ]. Advantages of long-term care by the burn surgeon and burn specialist team include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent evaluation and prompt surgical management of burn wound contractures not amenable or responsive to aggressive rehabilitation exercises",
"     </li>",
"     <li>",
"      Timely management of late burn wound complications (eg, late contractures, graft loss)",
"     </li>",
"     <li>",
"      Optimization of nutritional support to avoid major loss of lean body mass as the hypermetabolic response persists",
"     </li>",
"     <li>",
"      Psychosocial support for managing re-immersion into society, and adjusting to scarring and disfigurement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delayed improvement in burn-specific health can be expected for most burn patients. In a prospective study that included 89 consecutive burn patients, preburn factors (eg, psychiatric disorders, major depression), length of hospital stay, hand injury, and posttraumatic stress disorder present at 12 months postburn were predictors of adverse long-term (2 to 7 years) burn-specific health in affect and personal relations domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Reconstruction of burn wounds is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1470803\">",
"    <span class=\"h1\">",
"     SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall mortality from a severe burn injury ranges from 3 to 55 percent, depending upon the extent (eg, size and depth) of the burn as well as the presence of inhalation injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/17\">",
"     17",
"    </a>",
"    ]. Previously, a patient with a 50 percent TBSA burn had a 50 percent mortality rate. However, the contemporary mortality rate for a young patient (age 0 to 14 years) with a 99 percent TBSA burn is 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival rates have improved with advancements in resuscitation, antimicrobials, and burn wound care, with a 50 percent decline in burn-related deaths and hospital admissions in the USA over the last 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/19\">",
"     19",
"    </a>",
"    ]. However, 50 percent of all deaths from burns occur within the first 10 days secondary to inadequate resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/17,20-22\">",
"     17,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example, in a retrospective review of 238 severely burned patients, the overall survival rate was 78.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/23\">",
"     23",
"    </a>",
"    ]. The contemporary survival rate for patients with &gt;95 percent TBSA burns was approximately 50 percent for children aged 14 years and younger, 75 percent in adults 45 to 64 years, and 30 percent TBSA in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35478/abstract/19,24,25\">",
"     19,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96426407\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a patient with a severe burn injury is a long-term process that addresses the local burn wound care as well as the systemic, psychologic, and social consequences of the injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A severe (major) burn as defined by the American Burn Association burn injury severity grading system includes (see",
"      <a class=\"local\" href=\"#H5673403\">",
"       'Definition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      25 percent total body surface area (TBSA) or greater, 10 to 40 years of age (excludes superficial burns, such as sun burn)",
"     </li>",
"     <li>",
"      20 percent TBSA or greater in children under 10 years and adults over 40 years of age (excludes superficial burns), 10 percent TBSA or greater full-thickness burns",
"     </li>",
"     <li>",
"      All burns involving eyes, ears, face, hands, feet, or perineum that are likely to result in cosmetic or functional impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If emergent management is not provided at a designated burn center, the patients that should be transferred to a burn center as soon as stabilized include (see",
"      <a class=\"local\" href=\"#H14168468\">",
"       'Triage criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Partial-thickness burns more than 10 percent of the total body surface area (TBSA)",
"     </li>",
"     <li>",
"      Burns involving the face, hands, feet, genitalia, perineum,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      major joints",
"     </li>",
"     <li>",
"      Concomitant burns and trauma (eg, fractures) in which the burn injury poses the greater immediate risk of morbidity and mortality. If the trauma poses the greater immediate risk, the patient may be initially stabilized in a trauma center before being transferred to a burn unit. Physician judgment is necessary in these cases and should be in conjunction with the regional medical control plan and triage protocols. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32070?source=see_link\">",
"       \"Overview and management strategies for the combined burn trauma patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23977?source=see_link\">",
"       \"Management principles for burns resulting from mass disasters and war casualties\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Special requirements, such as social, emotional, or long-term rehabilitative needs.",
"     </li>",
"     <li>",
"      Children who require qualified pediatric personnel and equipment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute management in the ICU includes continuation of respiratory support, fluid resuscitation, cardiovascular stabilization, pain control, and local management of burn wounds initiated in the emergency department. The goal of the ICU care is to maintain end-organ perfusion and prevent burn shock. (See",
"      <a class=\"local\" href=\"#H1607614\">",
"       'Acute management in the ICU'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatient management focuses on wound healing, enteral nutrition, and rehabilitation. (See",
"      <a class=\"local\" href=\"#H1469902\">",
"       'Inpatient nonacute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term management includes management of long-term wound complications (eg, contractures), optimization of nutritional support, and psychosocial support to return to work and for re-immersion into society. (See",
"      <a class=\"local\" href=\"#H1469926\">",
"       'Long-term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jeschke MG, Williams FN, Gauglitz GG, Herndon DN. Burns. In: Sabiston Textbook of Surgery, Townsend M, Beauchamp RD, Evers MB, Kenneth ML (Eds), Elsevier, Philadelphia, PA 2012. Vol 19, p.521.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/2\">",
"      Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/3\">",
"      McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/4\">",
"      Hospital and prehospital resources for optimal care of patients with burn injury: guidelines for development and operation of burn centers. American Burn Association. J Burn Care Rehabil 1990; 11:98.",
"     </a>",
"    </li>",
"    <li>",
"     Mlcak R, M Buffalo, C Jimenez. Pre-hospital management, transportation and emergency care. In: Total Burn Care, 4th ed, Herndon DN.  (Ed), 2012.",
"    </li>",
"    <li>",
"     American Burn Association: Burn center referal criteria ameriburn.org (Accessed on July 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/7\">",
"      Faucher LD, Conlon KM. Practice guidelines for deep venous thrombosis prophylaxis in burns. J Burn Care Res 2007; 28:661.",
"     </a>",
"    </li>",
"    <li>",
"     DVT PE prophylaxis. University of Toronto Trauma Program Protocols. Sunnybrook Health Sciences Center. Department of Surgery. m.trauma.utoronto.ca (Accessed on December 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/9\">",
"      Bushwitz J, LeClaire A, He J, Mozingo D. Clinically significant venous thromboembolic complications in burn patients receiving unfractionated heparin or enoxaparin as prophylaxis. J Burn Care Res 2011; 32:578.",
"     </a>",
"    </li>",
"    <li>",
"     Saffle JR, Graves C, Cochran A. Nutritional support of the burned patient. In: Total Burn Care, Herndon DN.  (Ed), Saunders Elsevier, Philadelphia 2012. p.333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/11\">",
"      Jeschke MG, Barrow RE, Herndon DN. Extended hypermetabolic response of the liver in severely burned pediatric patients. Arch Surg 2004; 139:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/12\">",
"      Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387.",
"     </a>",
"    </li>",
"    <li>",
"     Barret J. Cost-containment and outcome measures. In: Total Burn Care, Herndon DN.  (Ed), Saunders Elsevier, Philadepphia 2012. p.706.",
"    </li>",
"    <li>",
"     Warden GD, Warner P. Functional sequelae and disability assessment. In: Total Burn Care, 4th, Herndon DN.  (Ed), Saunders Elsevier, Philadelphia 2012. p.699.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/15\">",
"      Williams FN, Jeschke MG, Chinkes DL, et al. Modulation of the hypermetabolic response to trauma: temperature, nutrition, and drugs. J Am Coll Surg 2009; 208:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/16\">",
"      Oster C, Willebrand M, Ekselius L. Burn-specific health 2 years to 7 years after burn injury. J Trauma Acute Care Surg 2013; 74:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/17\">",
"      Kraft R, Herndon DN, Al-Mousawi AM, et al. Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study. Lancet 2012; 379:1013.",
"     </a>",
"    </li>",
"    <li>",
"     Lee JO, Dibildox M, Jomenez C, et al. Operative wound management. In: Total Burn Care, 4th, Herndon DN.  (Ed), Saunders Elsevier, Philadelphia 2012. p.1013.",
"    </li>",
"    <li>",
"     Chung K, Steven Wolf. Critical care in the severely burned :  Organ support and management of complications. In: Total Burn Care, 4th ed, Herndon DN.  (Ed), 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/20\">",
"      Gore DC, Hawkins HK, Chinkes DL, et al. Assessment of adverse events in the demise of pediatric burn patients. J Trauma 2007; 63:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/21\">",
"      Williams FN, Herndon DN, Hawkins HK, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009; 13:R183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/22\">",
"      Wolf SE, Rose JK, Desai MH, et al. Mortality determinants in massive pediatric burns. An analysis of 103 children with &gt; or = 80% TBSA burns (&gt; or = 70% full-thickness). Ann Surg 1997; 225:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/23\">",
"      Mustonen KM, Vuola J. Acute renal failure in intensive care burn patients (ARF in burn patients). J Burn Care Res 2008; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/24\">",
"      Bull JP, Squire JR. A Study of Mortality in a Burns Unit: Standards for the Evaluation of Alternative Methods of Treatment. Ann Surg 1949; 130:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35478/abstract/25\">",
"      Miller SF, Bessey PQ, Schurr MJ, et al. National Burn Repository 2005: a ten-year review. J Burn Care Res 2006; 27:411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16320 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35478=[""].join("\n");
var outline_f34_41_35478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H96426407\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2965687942\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5673403\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14168772\">",
"      EMERGENCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14168468\">",
"      TRIAGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1607614\">",
"      ACUTE MANAGEMENT IN THE ICU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1469902\">",
"      INPATIENT NONACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1469926\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1470803\">",
"      SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96426407\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/54/18285\" title=\"table 2\">",
"      University of Washington Burn Center Pain Medication Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/50/30508\" title=\"table 3\">",
"      Opioids children with burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34169?source=related_link\">",
"      Burn pain: Principles of pharmacologic and nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21417?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of burn wound sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15716?source=related_link\">",
"      Evaluating nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23977?source=related_link\">",
"      Management principles for burns resulting from mass disasters and war casualties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32070?source=related_link\">",
"      Overview and management strategies for the combined burn trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38695?source=related_link\">",
"      Paradigm-based treatment approaches for burn pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18409?source=related_link\">",
"      Primary operative management of hand burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35479="Classification and treatment of ovarian hyperstimulation syndrome";
var content_f34_41_35479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and treatment of ovarian hyperstimulation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Vaclav Insler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Bruno Lunenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35479/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/41/35479/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the problems resulting from gonadotropin therapy for induction of ovulation are related to the development, luteinization, and ovulation of multiple follicles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most serious complications of excessive ovarian stimulation are a high incidence of multiple gestation and ovarian hyperstimulation syndrome (OHSS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple gestation is a concern because these pregnancies are associated with increased rates of perinatal mortality and morbidity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link\">",
"       \"Twin pregnancy: Prenatal issues\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12842?source=see_link\">",
"       \"Triplet pregnancy: Mid and late pregnancy complications and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OHSS refers to a combination of ovarian enlargement due to multiple ovarian cysts and an acute fluid shift out of the intravascular space (",
"      <a class=\"graphic graphic_table graphicRef51404 \" href=\"mobipreview.htm?11/1/11291\">",
"       table 1",
"      </a>",
"      ). It is a potentially life-threatening complication of ovulation induction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification and treatment of established OHSS will be reviewed here. The pathogenesis and prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian hyperstimulation is classified into three grades based upon the severity of symptoms, signs, and laboratory findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/1\">",
"     1",
"    </a>",
"    ]. The cardinal event in the genesis of OHSS is ovarian enlargement with ascites and hypovolemia resulting from an acute fluid shift out of the intravascular space. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Grade I ovarian hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade I (mild hyperstimulation) is characterized by bilateral ovarian enlargement with multiple follicular and corpus luteum cysts measuring up to 5 by 5 cm. Laboratory findings include a serum estradiol (E2) concentration greater than 1500",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (6000",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    and progesterone concentration greater than 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (115",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the early part of the luteal phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Grade II ovarian hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade II (moderate hyperstimulation) describes ovaries enlarged up to 12 by 12 cm, accompanied by abdominal discomfort and gastrointestinal symptoms (eg, nausea, vomiting, and diarrhea). A sudden increase in weight of more than 3 kg may be an early sign of moderate hyperstimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Grade III ovarian hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade III (severe hyperstimulation) is defined by the presence of large ovarian cysts (more than 12 by 12 cm), ascites, and, in some patients, pleural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial effusion, electrolyte imbalance (hyponatremia, hyperkalemia), hypovolemia, and hypovolemic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Marked hemoconcentration, increased blood viscosity, and thromboembolic phenomena, including disseminated intravascular coagulation, occur in the most severe cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous regression occurs over 10 to 14 days, but may take longer if implantation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148386197\">",
"    <span class=\"h3\">",
"     Pulmonary manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with severe OHSS involving the lungs display an extraparenchymal restrictive type of pulmonary dysfunction due to intraabdominal or pleural fluid accumulation, which limits descent of the diaphragm and expansion of the lungs. This causes uncoordinated lung ventilation and atelectasis leading to ventilation-perfusion mismatch and hypoxemia.",
"   </p>",
"   <p>",
"    Pulmonary infection, thromboembolism, or adult respiratory distress syndrome (ARDS) may further complicate the clinical picture. As an example, one study of 209 patients with severe OHSS found 4 percent had lobar pneumonia, 2 percent had ARDS, and 2 percent had pulmonary thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinical manifestations included dyspnea, tachypnea, moderate hypoxemia, increased alveolar-arterial oxygen difference, hypocarbia, respiratory alkalosis, and metabolic compensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148386264\">",
"    <span class=\"h3\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of ascites is reflected by the woman's weight gain: an initial gain of more than 3 kg following hCG administration should be considered a warning sign of developing OHSS and warrants close observation. Women with severe OHSS can gain as much as 15 to 20 kg over 5 to 10 days.",
"   </p>",
"   <p>",
"    Increased intraabdominal pressure from ascites causes maternal discomfort, which may be severe, and also can have hemodynamic effects on the maternal circulation (eg, impede renal vein outflow) and can compromise pulmonary function resulting in hypoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148386570\">",
"    <span class=\"h3\">",
"     Thromboembolic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic events are the most serious, but rarest, complications of OHSS. Thromboses can occur in either the arterial (25 percent) or venous (75 percent) circulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and may lead to permanent neurologic injury or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/8\">",
"     8",
"    </a>",
"    ]. The cause of these thromboembolic events is not fully established; however, it is probably related to hemoconcentration and hypercoagulation and associated with elevated estrogen concentrations. One study found high levels of factor V, platelets, fibrinogen, profibrinolysin, fibrinolytic inhibitors, and increased thromboplastin generation in women with OHSS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/9\">",
"     9",
"    </a>",
"    ]. All of these findings may be regarded as a result of hemoconcentration and the majority of them are also a consequence of high estrogen levels.",
"   </p>",
"   <p>",
"    Women with genetic thrombophilia (eg, antithrombin III deficiency, factor V Leiden mutation, protein C or S deficiency) are most prone to developing thromboembolic events in predisposing situations (eg, use of oral contraceptive pills, surgery). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some fertility clinics perform screening for thrombophilia before starting ovulation (superovulation) induction therapy since OHSS is a risk factor for thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thromboembolic complications of OHSS have been reported in the internal jugular, subclavian, axillary, and mesenteric vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. In one series of five cases of internal jugular vein thrombosis presenting at 7 to 10 weeks gestation after IVF, two occurred in women who had not had OHSS but had an underlying thrombophilia, while three occurred in women with severe OHSS and no underlying thrombophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Thromboemboli'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1151264691\">",
"    <span class=\"h4\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic stroke has been reported in some women with severe OHSS, including three case reports of middle cerebral artery thrombosis in women who developed hyperstimulation after in vitro fertilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidences of moderate and severe ovarian hyperstimulation compiled from more than 11,300 ovulation induction cycles are 3.1 to 6 percent and 0.25 to 1.8 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/1\">",
"     1",
"    </a>",
"    ]. In one report, the incidence of severe OHSS with ovulation induction appeared to be stable over time, while the incidence in the setting of in vitro fertilization increased from 0.06 percent in 1987 to 0.24 percent in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Sonographic monitoring of ovulation induction could help to reduce the incidence of OHSS; however, this ability is counterbalanced by the desire to achieve pregnancy in infertile couples with the fewest number of cycles. In one study, as an example, the pregnancy rate in hyperstimulated cycles was threefold higher than in nonhyperstimulated cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inducing mild OHSS appears beneficial for increasing pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, mild hyperstimulation has been renamed \"superovulation\" or \"controlled ovarian hyperstimulation\" to distinguish it from excessive ovarian stimulation associated with morbid sequelae. Controlled ovarian hyperstimulation is used for in vitro fertilization protocols and for treatment of unexplained, cervical, and some forms of male infertility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, mild hyperstimulation also raises the incidence of high-order multiple pregnancy (ie, more than two fetuses), which can result in more spontaneous abortions and perinatal complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11718?source=see_link\">",
"     \"Triplet pregnancy: Early pregnancy management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12842?source=see_link\">",
"     \"Triplet pregnancy: Mid and late pregnancy complications and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, one series found superovulation and intrauterine insemination led to twins and triplets-or-more in 20 and 10 percent, respectively, of resulting pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/18\">",
"     18",
"    </a>",
"    ]. By comparison, the incidence of twins and triplets in spontaneously conceived pregnancies is approximately",
"    <span class=\"nowrap\">",
"     1/90",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/8000,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Another study reported the frequency of spontaneous abortion was higher among triplets than twins, 25 versus 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, over 90 percent of triplets have birth weights less than 2500 grams (ie, low birth weight LBW) and 40 percent are less than 1500 grams (ie, very low birth weight VLBW) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/20\">",
"     20",
"    </a>",
"    ], whereas the rates of LBW and VLBW in the general population are approximately 7 and 1.5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe hyperstimulation further worsens pregnancy outcome. This was illustrated in a retrospective review of 163 women with severe OHSS in whom the frequency of singletons, twins, triplets, and quadruplets was 42, 34, 17, and 7 percent, respectively, with a miscarriage rate of 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A controlled study did not show increased feto-maternal morbidity during the second and third trimesters of gestation among patients who developed OHSS compared to IVF-treated patients without excessive ovarian stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/23\">",
"     23",
"    </a>",
"    ]. However, uncontrolled studies suggested these pregnancies had a higher rate of gestational diabetes and pregnancy-associated hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. More data are needed to better understand whether OHSS affects the frequency of late pregnancy complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment of OHSS is primary prevention. Preventing ovulation by withholding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) is an effective method of avoiding hyperstimulation in overstimulated ovaries. Alternatively, aspiration of follicles 36 hours after administration of the ovulatory dose of hCG may lower the risk of developing clinical hyperstimulation by reducing the mass of luteinized granulosa cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OHSS is a self-limiting disease; thus, treatment should be symptomatic and conservative. Medical therapy suffices for most patients, with laparotomy reserved for catastrophic complications, such as ovarian torsion or rupture and internal hemorrhage. Women with severe symptoms often require intensive medical care. Vaginal intercourse is restricted in all grades of OHSS because of the risk of cyst rupture. Patients should also avoid impact-type activities or strenuous exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Grade I hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is supportive, as needed. However, mild ovarian hyperstimulation can develop into moderate or severe disease, especially if conception ensues. Therefore, women with mild disease (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Grade I ovarian hyperstimulation'",
"    </a>",
"    above) should be observed for enlarging abdominal girth, acute weight gain, and abdominal discomfort on an ambulatory basis for at least two weeks or until the appearance of menstrual bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Grade II hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of moderate hyperstimulation (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Grade II ovarian hyperstimulation'",
"    </a>",
"    above) consists of observation, bed rest, provision of adequate fluids, and sonographic monitoring of cyst size. Serum electrolytes, hematocrit, and creatinine should also be evaluated. Some clinicians have outpatients keep track of their fluid intake and output; intake or output less than 1000",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    or a discrepancy in fluid balance greater than 1000",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    would be a cause for concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of resolution is apparent when the cysts become smaller on two consecutive ultrasound examinations and clinical symptoms recede. In contrast, early detection of progression to the severe form of the syndrome is marked by continuous weight gain (two pounds or more a day), increase in severity of existing symptoms, or the appearance of new symptoms, such as vomiting, diarrhea, and dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Grade III hyperstimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatment of severe hyperstimulation (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Grade III ovarian hyperstimulation'",
"    </a>",
"    above) is directed toward:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining blood volume while correcting the disturbed fluid and electrolyte balance",
"     </li>",
"     <li>",
"      Relieving secondary complications of ascites and hydrothorax",
"     </li>",
"     <li>",
"      Preventing thromboembolic phenomena",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory tests are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef59064 \" href=\"mobipreview.htm?2/62/3051\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to frequent monitoring of vital signs and",
"    <span class=\"nowrap\">",
"     intake/output,",
"    </span>",
"    weight and abdominal girth should be checked daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia is caused by extravasation of intravascular fluid (\"third-spacing\") and is associated with ascites, hemoconcentration, decreased central venous pressure, low blood pressure, and tachycardia. Decreased renal perfusion leads to increased reabsorption of sodium and water in the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/25\">",
"     25",
"    </a>",
"    ], resulting in oliguria and a low urinary sodium concentration.",
"   </p>",
"   <p>",
"    Fluid balance should be carefully monitored by net fluid flow",
"    <span class=\"nowrap\">",
"     (intake/output",
"    </span>",
"    record), weight and girth measurements, and hematocrit examinations. A central venous pressure catheter may be required in women who are hemodynamically unstable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, one to two liters of isotonic fluid is given to such women in the first hour to rapidly restore tissue perfusion. Further fluids optimally should be given while monitoring the central venous or pulmonary capillary wedge pressure. Fluid repletion should continue at the initial rapid rate as long as the cardiac filling pressures and the systemic blood pressure remain low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma expanders such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , human albumin (200 mL of 25 percent albumin over four hours), and plasma (500 to 1000 mL over 24 hours) supplemented with appropriate electrolytes should be administered early and repeated as needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .) The effect of this treatment may be enhanced by the addition of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , which blocks prostaglandin synthesis and reduces capillary permeability. Hematocrit should be monitored every four hours; plasma expanders can be stopped when the hematocrit is less than 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diuretic agents are not recommended since fluid in the third space is not affected by these drugs. Furthermore, most diuretics act at the distal tubule with minimal effect on the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, the artificially induced diuresis may further diminish the intravascular volume, but may be unable to relieve ascites or hydrothorax. Renal failure may respond to a dopamine drip (0.18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/27\">",
"     27",
"    </a>",
"    ]. Oral docarpamine administration could be one of the options in the management of patients with OHSS requiring dopamine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ovarian enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cysts associated with grade III OHSS are so large and brittle that surgical attempts at a palliative procedure usually result in oophorectomy. Therefore, surgery should be avoided unless there is torsion or cyst rupture with hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .) Torsion is characterized by ovarian enlargement, abdominal pain, nausea, progressive leukocytosis, and anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/29\">",
"     29",
"    </a>",
"    ]. Treatment may require oophorectomy, although in many cases the ovary can be saved by unwinding at laparotomy or laparoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Approach to ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of ascites is reflected by the woman's weight gain: an initial gain of more than 3 kg following hCG administration should be considered a warning sign of developing OHSS and warrants close observation. Women with severe OHSS can gain as much as 15 to 20 kg over 5 to 10 days. (See",
"    <a class=\"local\" href=\"#H1148386264\">",
"     'Ascites'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Improvement in creatinine clearance, urine volume, and weight loss in women with severe OHSS treated with abdominal paracentesis has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, other authors have recommended that abdominal paracentesis for drainage of ascites not be performed because of the danger of intraperitoneal hemorrhage from inadvertent puncture of the large ovarian cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The danger of blind paracentesis has been reduced by using sonographic guidance for the procedure. In our practice, we have not had a single case of intraperitoneal hemorrhage requiring surgical intervention following sonographically guided drainage of ascites in women with severe hyperstimulation syndrome. Paracentesis resulted in a marked improvement of renal function (due to increased venous return), blood osmolarity, and hemoconcentration, as well as relief of dyspnea and abdominal discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study described 42 cases of severe OHSS treated by transvaginal sonographically guided aspiration of ascites and intravenous fluid infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/35\">",
"     35",
"    </a>",
"    ]. This treatment relieved symptoms, reduced the hematocrit, improved renal clearance and urine output, and shortened the duration of hospital stay. Other authors have reinfused the withdrawn ascitic fluid (after microfiltration) and reported relief of symptoms and improvement of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pleural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, women with severe OHSS involving the lungs display an extraparenchymal restrictive type of pulmonary dysfunction due to intraabdominal or pleural fluid accumulation, which limits descent of the diaphragm and expansion of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1148386197\">",
"     'Pulmonary manifestations'",
"    </a>",
"    above.) Pleural effusions should be drained to relieve dyspnea. Paracentesis may also be useful in alleviating breathing difficulties in patients with ascites and hydrothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Thromboemboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic events are the most serious, but rarest, complications of OHSS. Thromboses can occur in either the arterial (25 percent) or venous (75 percent) circulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and may lead to permanent neurologic injury or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin, antiembolism stockings, and or intermittent pneumatic compression boots should be considered to minimize the risk of venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment of thromboembolic complications is anticoagulation with heparin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a period of several days, third space fluid begins to re-enter the intravascular space, hemoconcentration reverses, and natural diuresis ensues. The patient feels better and her appetite and ability to take oral fluids improve. Intravenous fluids are tapered as oral intake increases. Some clinicians limit oral intake to 1000",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    at this time to facilitate diuresis and maintain euvolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"     2",
"    </a>",
"    ]. Complete resolution typically takes 10 to 14 days from the onset of initial symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carefully maintaining blood volume, correcting electrolyte imbalance, and relieving secondary complications of ascites and hydrothorax are generally sufficient for supporting the patient during the severe phase of ovarian hyperstimulation. Anticoagulant therapy is usually unnecessary if these therapies are promptly employed. Blood coagulation may be monitored because of the danger of disseminated intravascular clotting.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lunenfeld, B, Insler, V, Glezerman, M. Diagnosis and treatment of functional infertility, 3rd ed, Blackwell Wissenschaft, Berlin 1993. p. 98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/2\">",
"      Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/3\">",
"      Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod 1997; 12:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/4\">",
"      Practice Committe of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2003; 80:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/5\">",
"      Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999; 71:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/6\">",
"      Aboulghar MA, Mansour RT, Serour GI, Amin YM. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum Reprod 1998; 13:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/7\">",
"      Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997; 12:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/8\">",
"      Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995; 27:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/9\">",
"      Phillips LL, Gladstone W, vande Wiele R. Studies of the coagulation and fibrinolytic systems in hyperstimulation syndrome after administration of human gonadotropins. J Reprod Med 1975; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/10\">",
"      Tang OS, Ng EH, Wai Cheng P, Chung Ho P. Cortical vein thrombosis misinterpreted as intracranial haemorrhage in severe ovarian hyperstimulation syndrome: case report. Hum Reprod 2000; 15:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/11\">",
"      Arya R, Shehata HA, Patel RK, et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol 2001; 115:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/12\">",
"      Jing Z, Yanping L. Middle cerebral artery thrombosis after IVF and ovarian hyperstimulation: a case report. Fertil Steril 2011; 95:2435.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/13\">",
"      Qazi A, Ahmed AN, Qazi MP, et al. Ischaemic stroke with ovarian hyperstimulation syndrome. J Pak Med Assoc 2008; 58:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/14\">",
"      Bartkova A, Sanak D, Dostal J, et al. Acute ischaemic stroke in pregnancy: a severe complication of ovarian hyperstimulation syndrome. Neurol Sci 2008; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/15\">",
"      Abramov Y, Elchalal U, Schenker JG. Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay? Hum Reprod 1999; 14:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/16\">",
"      Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/17\">",
"      Tulandi T, McInnes RA, Arronet GH. Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin. Int J Fertil 1984; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/18\">",
"      Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999; 340:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/19\">",
"      Yaron Y, Bryant-Greenwood PK, Dave N, et al. Multifetal pregnancy reductions of triplets to twins: comparison with nonreduced triplets and twins. Am J Obstet Gynecol 1999; 180:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Contribution of assisted reproductive technology and ovulation-inducing drugs to triplet and higher-order multiple births--United States, 1980-1997. MMWR Morb Mortal Wkly Rep 2000; 49:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/21\">",
"      Guyer B, Freedman MA, Strobino DM, Sondik EJ. Annual summary of vital statistics: trends in the health of Americans during the 20th century. Pediatrics 2000; 106:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/22\">",
"      Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1998; 70:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/23\">",
"      Wiser A, Levron J, Kreizer D, et al. Outcome of pregnancies complicated by severe ovarian hyperstimulation syndrome (OHSS): a follow-up beyond the second trimester. Hum Reprod 2005; 20:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/24\">",
"      Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG 2000; 107:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/25\">",
"      Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril 1969; 20:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/26\">",
"      Engel T, Jewelewicz R, Dyrenfurth I, et al. Ovarian hyperstimulation syndrome. Report of a case with notes on pathogenesis and treatment. Am J Obstet Gynecol 1972; 112:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/27\">",
"      Ferraretti AP, Gianaroli L, Diotallevi L, et al. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/28\">",
"      Tsunoda T, Shibahara H, Hirano Y, et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003; 17:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/29\">",
"      Mashiach S, Bider D, Moran O, et al. Adnexal torsion of hyperstimulated ovaries in pregnancies after gonadotropin therapy. Fertil Steril 1990; 53:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/30\">",
"      Chapron C, Capella-Allouc S, Dubuisson JB. Treatment of adnexal torsion using operative laparoscopy. Hum Reprod 1996; 11:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/31\">",
"      Thaler I, Yoffe N, Kaftory JK, Brandes JM. Treatment of ovarian hyperstimulation syndrome: the physiologic basis for a modified approach. Fertil Steril 1981; 36:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/32\">",
"      Levin I, Almog B, Avni A, et al. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 2002; 77:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/33\">",
"      Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978; 30:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/34\">",
"      Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989; 51:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/35\">",
"      Aboulghar MA, Mansour RT, Serour GI, et al. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 1993; 81:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/36\">",
"      Aboulghar MA, Mansour RT, Serour GI, et al. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992; 58:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/37\">",
"      Fukaya T, Chida S, Terada Y, et al. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 1994; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35479/abstract/38\">",
"      Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989; 51:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7433 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35479=[""].join("\n");
var outline_f34_41_35479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Grade I ovarian hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Grade II ovarian hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Grade III ovarian hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1148386197\">",
"      - Pulmonary manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1148386264\">",
"      - Ascites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1148386570\">",
"      - Thromboembolic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1151264691\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Grade I hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Grade II hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Grade III hyperstimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ovarian enlargement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Approach to ascites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Thromboemboli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Resolution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7433\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7433|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/1/11291\" title=\"table 1\">",
"      Clinical findings OHSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/62/3051\" title=\"table 2\">",
"      Lab tests in severe OHSS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=related_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11718?source=related_link\">",
"      Triplet pregnancy: Early pregnancy management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12842?source=related_link\">",
"      Triplet pregnancy: Mid and late pregnancy complications and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35480="Dilation and curettage";
var content_f34_41_35480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dilation and curettage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     Dale W Stovall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35480/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/41/35480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gynecologist has a variety of tools available for evaluation and treatment of women with abnormal uterine bleeding. Dilation and curettage (D&amp;C) will be reviewed here. Office procedures for endometrial sampling and an overview of diagnostic approaches to endometrial evaluation, including both noninvasive and invasive assessment, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;D&amp;C has both diagnostic and therapeutic indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of equipment and techniques for office based endometrial sampling has obviated the need for diagnostic D&amp;C in most patients. Numerous studies have shown that the endometrium is adequately evaluated with sampling techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are still some indications for diagnostic D&amp;C, such as in women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a nondiagnostic office biopsy who are at high risk of endometrial carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With endometrial hyperplasia, and in whom endometrial cancer needs to be excluded. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link\">",
"       \"Classification and diagnosis of endometrial hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With insufficient tissue for analysis on office biopsy.",
"     </li>",
"     <li>",
"      In whom cervical stenosis prevents the completion of an office biopsy.",
"     </li>",
"     <li>",
"      For whom another operative procedure, such as hysteroscopy or laparoscopy, is deemed necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic D&amp;C should be done with hysteroscopy to obtain a visual image of the endometrial cavity and to exclude focal disease. Hysteroscopy thus turns a \"blind\" procedure into one allowing directed curettage. This helps to prevent missing unsuspected polyps and insures that the most visibly abnormal areas are sampled. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Therapeutic indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation and",
"    <span class=\"nowrap\">",
"     evacuation/curettage",
"    </span>",
"    (D&amp;EC) is used as a therapeutic modality in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of incomplete, inevitable, missed, septic, and induced abortions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"       \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4453?source=see_link\">",
"       \"Surgical termination of pregnancy: First trimester\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial treatment of molar pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link\">",
"       \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporary management of women with prolonged or excessive vaginal bleeding unresponsive to hormonal therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11305?source=see_link&amp;anchor=H19#H19\">",
"       \"Managing an episode of severe or prolonged uterine bleeding\", section on 'Uterine curettage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suction curettage (without dilation) may be used to manage postpartum hemorrhage due to retained products of conception. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only major contraindication to D&amp;C is viable and desired intrauterine pregnancy. Bleeding diathesis is a relative contraindication since bleeding may be excessive in such patients. The management of these patients, including possibly temporarily withholding anticoagulants, needs to be decided on a case by case basis in consultation with the patient's other physicians. In the presence of acute vaginal, cervical, or pelvic infection, the procedure should be deferred, if possible, until the infection has been treated. One exception is therapeutic D&amp;C to remove infected products of conception. Cervical cancer, if obstructing the endocervical canal, also represents a contraindication as heavy bleeding or perforation may occur. In these patients cervical biopsy would be diagnostic and D&amp;C would be unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;D&amp;C is generally performed under general or regional anesthesia; therefore, the patient should limit oral intake prior to the procedure. The American Society of Anesthesiologists recommends no intake of clear liquids in the two hours before and no solid food in the six hours before procedures involving anesthesia (eight hours in pregnant women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/1\">",
"     1",
"    </a>",
"    ]. An empty stomach is also desirable for patients who plan paracervical block anesthesia in case the block is inadequate and another anesthetic or sedative needs to be administered.",
"   </p>",
"   <p>",
"    Prophylactic antibiotics are not necessary.",
"   </p>",
"   <p>",
"    Preoperative laboratory tests are generally not necessary, except as indicated by the patient's age and medical condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H10#H10\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, regional, or paracervical block anesthesia can be used. The type of anesthesia chosen depends upon the indication for the procedure, as well as the medical history of the woman. General anesthesia provides complete muscular relaxation, which is important when examination under anesthesia is a critical element of the procedure. Regional anesthesia provides adequate muscular blockade without the pulmonary and gastrointestinal risks of general anesthesia.",
"   </p>",
"   <p>",
"    Paracervical block with intravenous conscious sedation is a convenient, inexpensive, and effective technique amenable to the outpatient setting (",
"    <a class=\"graphic graphic_picture graphicRef69403 \" href=\"mobipreview.htm?33/29/34261\">",
"     picture 1",
"    </a>",
"    ). The block anesthetizes uterine nerves as they pass through Frankenhauser's plexus in the cervix.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/17/3350?source=see_link\">",
"     Chloroprocaine",
"    </a>",
"    1 percent (Nesacaine) provides an improved margin of safety over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    because it is rapidly metabolized and theoretically has a lower risk of toxicity if an inadvertent intravascular injection occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of pregnancy termination\", section on 'Paracervical block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been a number of randomized controlled trials comparing the analgesic effects of intrauterine instillation of anesthetics (eg, 3 to 5 mL of 2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or 2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    ) versus placebo. Although about half of the trials showed that topical anesthesia significantly reduced the patient's perception of pain during an intrauterine procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/2-7\">",
"     2-7",
"    </a>",
"    ], the other half did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A D&amp;C is performed with the woman in the dorsal lithotomy position. Care must be taken to avoid over-abduction of the hip joint when placing her in stirrups. Furthermore, the lateral aspect of the legs should not rest against the stirrups as this can cause peroneal nerve injury with subsequent foot-drop. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An examination under anesthesia is performed first. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20499?source=see_link\">",
"     \"Pelvic examination under anesthesia\"",
"    </a>",
"    .) The size, shape, and position of the uterus are noted, with particular attention to the axis of the cervix and flexion of the fundus. Appreciation of the latter is critical to reduce the incidence of uterine perforation. The size, shape, and consistency of the adnexa are determined next.",
"   </p>",
"   <p>",
"    After the examination, the perineum, vagina, and cervix are cleansed with an aseptic solution and drapes are placed; it is not necessary to shave vulvar hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal retractors or a speculum is inserted into the vagina to provide exposure. The type of vaginal retraction required for adequate exposure depends upon the woman's body habitus and the procedure being performed. The Graves speculum provides adequate exposure of the cervix and is well-suited for women undergoing a therapeutic D&amp;EC.",
"   </p>",
"   <p>",
"    When a hysteroscopy is being performed in conjunction with the D&amp;C, a side-open Graves speculum provides a maximum range of motion to the hysteroscope during the examination and is easily removed. Alternatively, a Sims retractor or an Auvard weighted speculum (",
"    <a class=\"graphic graphic_figure graphicRef58171 \" href=\"mobipreview.htm?31/4/31808\">",
"     figure 1",
"    </a>",
"    ) can be used in conjunction with Schieden vaginal side wall retractors (",
"    <a class=\"graphic graphic_picture graphicRef68514 \" href=\"mobipreview.htm?16/32/16900\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38440?source=see_link\">",
"     \"Surgical instruments for gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tenaculum",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tenaculum is generally used to grasp the anterior lip of the cervix (",
"    <a class=\"graphic graphic_picture graphicRef77725 \" href=\"mobipreview.htm?16/3/16432\">",
"     picture 3",
"    </a>",
"    ). The single tooth tenaculum is useful in women with a small amount of cervical tissue (eg, postmenopausal women, women who have undergone previous cone biopsy); however, this instrument is more likely to cause a laceration of the cervix. We prefer the Bierer (multi-toothed) tenaculum because it is less traumatic. Ring forceps may also be used to grasp the cervix, particularly in the pregnant patient in whom the soft, engorged cervix is prone to laceration and hemorrhage. In some patients, such as women with a lacerated or torn anterior lip, it will be necessary to attach the tenaculum to the posterior cervical lip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endocervical curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;If indicated, an endocervical curettage (ECC) is performed before dilation of the cervix to avoid contamination of the histologic specimen with endometrial cells. A Kevorkian-Younge curette is introduced into the cervical canal up to the internal os (",
"    <a class=\"graphic graphic_picture graphicRef62722 \" href=\"mobipreview.htm?26/8/26753\">",
"     picture 4",
"    </a>",
"    ). This instrument is slightly curved and narrow to accommodate the small endocervical canal. All four quadrants of the canal are scraped and the specimen placed on a pad (eg, Telfa).",
"   </p>",
"   <p>",
"    The ECC is performed to detect the presence of endometrial carcinoma extending into the cervical canal or the presence of endocervical pathology. The clinical usefulness of the ECC has been questioned. It is predictive of cervical involvement of endometrial carcinoma when the histology demonstrates stromal involvement. However, numerous investigators have demonstrated a false-positive rate of 80 percent when tumor is detected on ECC alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/13\">",
"     13",
"    </a>",
"    ]. Since surgical staging of endometrial carcinoma does not require a separate ECC, the need for an ECC is only relevant for patients who cannot undergo a full staging procedure. If there is a clinical indication for D&amp;C at the time of a cervical conization, the conization should be performed prior to the D&amp;C to preserve cervical architecture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sounding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction is applied to the tenaculum to align the axis of the cervix and the uterine canal. The uterus is sounded to document the size and confirm the position. The sound is held between the thumb and the index finger to avoid application of excessive pressure. In some cases, dilation of the cervix may be required before sounding the uterus. A normal uterus sounds to 8 to 9 cm.",
"   </p>",
"   <p>",
"    The pregnant uterus, however, should",
"    <strong>",
"     never",
"    </strong>",
"    be sounded because there is a high risk of uterine perforation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cervical dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After sounding the uterus, the cervix is dilated. The most common dilators are the Pratt and Hegar (",
"    <a class=\"graphic graphic_picture graphicRef55448 \" href=\"mobipreview.htm?15/57/16277\">",
"     picture 5",
"    </a>",
"    ). The Pratt dilator comes in sizes ranging from 13 to 43 French; each French unit is equivalent to 0.33 mm in diameter. It is characterized by a gradual taper at the end of the instrument. By comparison, Hegar dilators have a blunt end and come in sizes ranging from 1 to 26 mm in diameter. We prefer the tapered end of the Pratt dilator to the Hegar dilator. The former has been shown to require less force for dilation and is less likely to cause a perforation of the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dilator is grasped in the middle of the instrument with the thumb and index finger (",
"    <a class=\"graphic graphic_figure graphicRef77607 \" href=\"mobipreview.htm?38/36/39493\">",
"     figure 2",
"    </a>",
"    ). The cervix is gradually dilated beginning with the #13 French Pratt dilator. The dilator should be inserted through the internal os, without entering the uterine cavity excessively. This is helpful in preventing uterine perforation and avoids damage to the endometrium, which obscures optimal visualization if hysteroscopic examination is also planned.",
"   </p>",
"   <p>",
"    The degree of cervical dilation is dependent upon the indication for the procedure. When diagnostic hysteroscopy and D&amp;C are performed, the dilation is conducted to a point at which the hysteroscope may be comfortably inserted. The #17 French Pratt dilator will easily accommodate a 5 mm hysteroscope or a #3 sharp curette.",
"   </p>",
"   <p>",
"    When products of conception are to be removed, the cervix is generally dilated to a diameter in millimeters equal to the gestational age of the uterus. Dilation is easily accomplished up to 9 mm, at which time the cervix may become difficult to dilate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/15\">",
"     15",
"    </a>",
"    ]. When cervical dilation beyond 9.0 mm is required (eg, second trimester pregnancy termination or operative hysteroscopy), osmotic dilators should be placed preoperatively to allow gradual, atraumatic cervical dilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of pregnancy termination\", section on 'Osmotic dilators'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical ripening agents (prostaglandins) may facilitate dilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hysteroscopy\", section on 'Cervical preparation and dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complicated cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stenotic cervical os if often present in postmenopausal patients and sometimes in women who have had previous cervical surgery. Stenosis increases the risk of cervical laceration and uterine perforation; therefore, these women are best dilated beginning with a series of small (1 to 4 mm) Hegar dilators.",
"   </p>",
"   <p>",
"    Having multiple types of cervical dilators available will enable the surgeon to find the optimal instrument to approach each specific clinical scenario. Tiny metal lacrimal duct probes are useful for identifying the cervical canal in women with severe stenosis. Also, if the os is tightly scarred, penetration of the external dimple with a number 11 scalpel blade facilitates much easier passage of dilators without undue force. Care must be taken to excise on the external dimple and not incise further into cervical tissue. Tapered Teflon dilators permit gradual and gentle dilation of a stenotic canal. The instrument should be inserted far enough to reach the full diameter at the internal os, but no further. Deep insertion of dilators presents a significant risk for perforation at the fundus, especially in a patient who is pregnant, postpartum, or breastfeeding patient. If dilators do not pass with gentle pressure, the surgeon should stop and reassess the uterine position, the amount of cervical traction, and the direction of insertion.",
"   </p>",
"   <p>",
"    Transabdominal ultrasound can be useful in guiding a difficult dilation and may be prudent in women with a previous perforation of the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/16\">",
"     16",
"    </a>",
"    ]. This technique is especially useful in completing a D&amp;C if a perforation is suspected or if there is a question as to the adequacy of the evacuation. Rarely it may be necessary to perform a conization to open the cervical canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Curettage",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Curettes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metal curettes are available in blunt and sharp styles, ranging in size from #1 to #6, with 1 being the smallest (",
"    <a class=\"graphic graphic_picture graphicRef68468 \" href=\"mobipreview.htm?39/63/40945\">",
"     picture 6",
"    </a>",
"    ). The curette is malleable, which allows the instrument to be bent slightly to conform to the ante- or retro-flexed uterus.",
"   </p>",
"   <p>",
"    Sharp curettes are typically used for gynecologic procedures, including first trimester pregnancy termination. The blunt curette is best suited for the removal of small fragments of retained products of conception in the second trimester and postpartum uterus, and is often used after suction curettage. The blunt edge prevents excessive removal of the basalis layer of the endometrium, which can occur in the soft postpartum uterus and lead to formation of intrauterine adhesions (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Intrauterine adhesions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Plastic suction curettes are used for initial removal of products of conception from the uterus. Some surgeons also prefer the suction curette for diagnostic curettage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/17\">",
"     17",
"    </a>",
"    ]. Suction curettes range in size from 2 to 16 mm in diameter. Curettes &le;6 mm are flexible while the larger curettes are rigid (",
"    <a class=\"graphic graphic_picture graphicRef69749 \" href=\"mobipreview.htm?26/26/27045\">",
"     picture 7",
"    </a>",
"    ). We prefer 6 to 8 mm curettes when performing suction curettage in a small uterus (less than 8 week size). When a larger rigid suction curette is used, the curved instrument provides better tactile sensation compared to the straight curette.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Sharp curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curettage is performed systematically beginning at the fundus. Even pressure is applied to the endometrial surface along the entire length of the uterus from the fundus to the internal cervical os (",
"    <a class=\"graphic graphic_figure graphicRef56727 \" href=\"mobipreview.htm?30/17/30997\">",
"     figure 3",
"    </a>",
"    ). The endometrial tissue is deposited on a Telfa pad, which should be placed in the vagina to catch any spillage. The entire surface of the endometrium is sampled by moving around the uterus in a consistent and systematic fashion.",
"   </p>",
"   <p>",
"    The curettage procedure is completed when the \"uterine cry\" (grittiness to palpation) is appreciated on all surfaces of the uterus. The size and shape of any submucous fibroids detected by tactile sensation should be noted as part of the operative note. Curettage followed by blind extraction with Randall polyp forceps (",
"    <a class=\"graphic graphic_picture graphicRef62722 \" href=\"mobipreview.htm?26/8/26753\">",
"     picture 4",
"    </a>",
"    ) improves the rate of detection of polyps over curettage alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study evaluating the surface area sampled in 50 patients undergoing prehysterectomy D&amp;C found that less than one-fourth of the cavity had been curetted in 16 percent of specimens; less than one-half of the cavity had been curetted in 60 percent; and less than three-quarters of the cavity had been effectively curetted in 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite these limitations, D&amp;C provides adequate sensitivity for detecting endometrial pathology because pathologic conditions usually cover a large proportion of the surface area of the endometrial cavity and are therefore detectable by sampling techniques. Focal pathologic processes may, however, go undetected by any blind procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Suction curettage",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnostic &mdash; Suction curettage may be used for diagnostic purposes. The preferred method uses the Pipelle device and is performed as an office procedure, usually without anesthesia or cervical dilation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=see_link\">",
"       \"Endometrial sampling procedures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The external cervical os is then checked for any evidence for excessive bleeding. The tenaculum is removed and the cervix is examined for any trauma. Bleeding from the tenaculum site generally responds to direct pressure or the application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    solution (Monsel's solution). Occasionally a suture or cautery is required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant uterus &mdash; Suction curettage is typically used for the evacuation of products of conception, such as for incomplete or missed spontaneous abortion or for early pregnancy termination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4453?source=see_link&amp;anchor=H3#H3\">",
"       \"Surgical termination of pregnancy: First trimester\", section on 'Curettage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large bore plastic cannulas (12 to 16 mm) are used for second trimester pregnancy termination or removal of retained placental",
"    <span class=\"nowrap\">",
"     fragments/membranes",
"    </span>",
"    postpartum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    .) These cannulas should not be inserted deeply into the pregnant or postpartum uterus due to the risk of perforation. Placing a hand on the fundus of the uterus during the procedure may help to decrease the risk of perforation when the uterus is large and assists with assessment of the changing uterine size and position. For the same reason, it is preferable to explore the uterus with a large curette instead of narrower instruments, such as forceps or a small suction cannula.",
"   </p>",
"   <p>",
"    The cannula is rotated 360 degrees around its long axis under vacuum pressures of 50 to 60 cm Hg. As tissue is evacuated, the uterus will contract and the suction curette may be advanced to the fundus. Rotation is continued until no more tissue is drawn into the cannula.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is usually begun as soon as the suction curettage is started and continued for one or more hours postoperatively. A few passes with a large blunt curette (eg, banjo curette) can be performed after the suction procedure to remove any remaining products of conception.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestational trophoblastic neoplasia &mdash; There are additional technical aspects of curettage in this setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=see_link&amp;anchor=H4#H4\">",
"       \"Gestational trophoblastic disease: Management of hydatidiform mole\", section on 'Procedure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are rare and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anesthesia related complications",
"     </li>",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Uterine perforation",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Formations of intrauterine adhesions",
"     </li>",
"     <li>",
"      Trophoblast embolization (if gestational trophoblastic disease present)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation of the uterus at the time of D&amp;C is the most common immediate complication. The rate of perforation varies with the indication for the procedure. Perforation is most common when attempting control of postpartum hemorrhage (5.1 percent), and is less frequent during diagnostic curettage (0.3 percent in the premenopausal patient and 2.6 percent in the postmenopausal patient) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The risk of perforation is increased in pregnancy due to softening of the uterine wall and the increased size of the endometrial cavity.",
"   </p>",
"   <p>",
"    Uterine perforation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cervical injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical injuries can arise as a direct result of dilation or from trauma during curettage. Cervical lacerations frequently occur when excessive traction is applied to the tenaculum. The single tooth tenaculum is particularly vulnerable to such injuries, therefore, we prefer the Bierer tenaculum.",
"   </p>",
"   <p>",
"    Lacerations can be managed with direct pressure, application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    solution, cautery, or, in severe cases, suture control. Lacerations that involve the cervical branch of the uterine artery can produce extensive hemorrhage that may be controlled with direct suture application, by placing hemostatic sutures at the internal os, or therapeutic embolization. Rarely, hysterectomy is required to control bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of cervical injury can be reduced by avoiding use of excessive force during dilation. The Pratt dilators generally require less force to insert into the cervix than Hegar dilators. Osmotic dilators are helpful in decreasing the force required to dilate the cervix and are useful when dilation of 9 mm or greater are anticipated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of pregnancy termination\", section on 'Osmotic dilators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection after dilation and curettage is rare. Although bacteremia has been demonstrated in 5 percent of D&amp;Cs, the incidence of septicemia is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/23\">",
"     23",
"    </a>",
"    ]. Very little is known about risk factors for infection in patients undergoing D&amp;C for diagnostic purposes. In one study, the use of a rigid versus flexible cannula, general versus local anesthesia, and resident versus attending physician were all associated with an increased risk of febrile morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No data support the routine use of prophylactic antibiotics in diagnostic D&amp;C, nor is subacute bacterial endocarditis (SBE) prophylaxis recommended for a routine diagnostic D&amp;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intrauterine adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asherman's syndrome refers to the presence of intrauterine adhesions that typically result from endometrial damage due to uterine surgery, especially after curettage. Most, if not all, cases of Asherman syndrome arise from curettage performed on the pregnant uterus. In one large series of women with intrauterine adhesions, the underlying etiology was related to curettage for incomplete abortion (50 percent), postpartum bleeding (24 percent), elective abortion (18 percent), missed abortion (6 percent), or hydatidiform mole (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/26\">",
"     26",
"    </a>",
"    ]. The remaining 2 percent of patients had various other etiologies.",
"   </p>",
"   <p>",
"    Curettage of the endometrium, especially within the first four weeks postpartum, can result in trauma to the basalis layer with subsequent granular tissue healing on opposing surfaces of the uterus, which eventually fuse to produce tissue bridges. These intrauterine adhesions range from filmy adhesions composed of endometrial tissue to dense adhesions consisting entirely of connective tissue. The resulting adherence of the uterine walls, with partial or complete obliteration of the uterine cavity, accounts for the menstrual abnormalities, frequent dysmenorrhea, infertility, and habitual abortion.",
"   </p>",
"   <p>",
"    Asherman syndrome is typically diagnosed by either hysterosalpingogram (HSG) or hysteroscopy. The combination of the two techniques is helpful since HSG shows the location and extent of the adhesions, while hysteroscopy provides information as to their character. Before the widespread use of hysteroscopy, careful D&amp;C of the uterus followed by the placement of an intrauterine Foley catheter along with estrogen therapy had been the mainstay of therapy. Current therapy for Asherman syndrome includes hysteroscopic resection of the adhesions under direct visualization followed by long-term estrogen administration to stimulate regrowth of endometrial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hysteroscopy\", section on 'Rigid versus flexible'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Trophoblastic embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare complication of D&amp;C of a molar pregnancy is embolization of trophoblastic tissue into the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/28\">",
"     28",
"    </a>",
"    ]. Fatalities from cardiovascular collapse due to trophoblastic embolization have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35480/abstract/29\">",
"     29",
"    </a>",
"    ]. Thyroid storm is also encountered rarely. For these reasons, D&amp;C for trophoblastic disease should be performed in a formal operating room, with full anesthesia support and patient monitoring available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may resume normal activities as soon as the effects of anesthesia have worn off and they are comfortable.",
"   </p>",
"   <p>",
"    Cramps are the most common side effect. They usually rapidly subside after the procedure, but may last for a day or two. Nonsteroidal antiinflammatory drugs provide adequate analgesia.",
"   </p>",
"   <p>",
"    Light bleeding can persist for several days. Heavy bleeding, such as saturating a sanitary pad within one hour more than once, is abnormal.",
"   </p>",
"   <p>",
"    The patient should call her provider if she develops fever (more than 100.4&ordm;F), cramps lasting longer than 48 hours, increasing pain, prolonged or heavy bleeding, or a foul-smelling vaginal discharge.",
"   </p>",
"   <p>",
"    Follow-up of patients with gestational trophoblastic disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/33/29202?source=see_link\">",
"       \"Patient information: Dilation and curettage (D and C) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/24/8578?source=see_link\">",
"       \"Patient information: Dilation and curettage (D and C) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Office based endometrial sampling, whenever feasible, is recommended over dilation and curettage for diagnosis of abnormal uterine bleeding. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If use of a large curette is planned, osmotic, rather than mechanical, cervical dilators are recommended for cervical dilation greater than 9 mm. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cervical dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sounding the pregnant uterus is not recommended because there is a high risk of uterine perforation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sounding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, suction and blunt curettes are recommended for use in the pregnant or postpartum uterus as they are less likely to cause uterine perforation or intrauterine adhesions. Traditionally, sharp curettes are used in nonpregnant women, but suction or blunt curettes are also acceptable. Endometrial pathology usually covers a large proportion of the surface area of the endometrial cavity and is therefore detectable by any of these sampling techniques, which have not been directly compared in randomized trials. Focal pathologic processes may, however, go undetected by any blind procedure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Curettage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perforation of the fundus of the uterus is the most common immediate complication. It should be suspected when there is a loss of resistance during instrumentation of the uterus, when an instrument is found to extend into the uterine cavity for a distance that is greater than the known depth of the uterus, or, obviously, if heavy bleeding or viscera are observed in the vagina. Laparoscopy or laparotomy is often necessary to look for and repair visceral or vascular injuries and to allow completion of the procedure under direct vision. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Uterine perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blunt curette is recommended for use in the pregnant and postpartum uterus. The blunt edge prevents excessive removal of the basalis layer of the endometrium, which can lead to formation of intrauterine adhesions. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Curettes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Intrauterine adhesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures. www.asahq.org/publicationsAndServices/practiceparam.htm. (Accessed July 14, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/2\">",
"      Zupi E, Luciano AA, Valli E, et al. The use of topical anesthesia in diagnostic hysteroscopy and endometrial biopsy. Fertil Steril 1995; 63:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/3\">",
"      Cicinelli E, Didonna T, Ambrosi G, et al. Topical anaesthesia for diagnostic hysteroscopy and endometrial biopsy in postmenopausal women: a randomised placebo-controlled double-blind study. Br J Obstet Gynaecol 1997; 104:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/4\">",
"      Trolice MP, Fishburne C Jr, McGrady S. Anesthetic efficacy of intrauterine lidocaine for endometrial biopsy: a randomized double-masked trial. Obstet Gynecol 2000; 95:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/5\">",
"      Dogan E, Celiloglu M, Sarihan E, Demir A. Anesthetic effect of intrauterine lidocaine plus naproxen sodium in endometrial biopsy. Obstet Gynecol 2004; 103:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/6\">",
"      Rattanachaiyanont M, Leerasiri P, Indhavivadhana S. Effectiveness of intrauterine anesthesia for pain relief during fractional curettage. Obstet Gynecol 2005; 106:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/7\">",
"      Hui SK, Lee L, Ong C, et al. Intrauterine lignocaine as an anaesthetic during endometrial sampling: a randomised double-blind controlled trial. BJOG 2006; 113:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/8\">",
"      Lau WC, Tam WH, Lo WK, Yuen PM. A randomised double-blind placebo-controlled trial of transcervical intrauterine local anaesthesia in outpatient hysteroscopy. BJOG 2000; 107:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/9\">",
"      Frishman GN, Spencer PK, Weitzen S, et al. The use of intrauterine lidocaine to minimize pain during hysterosalpingography: a randomized trial. Obstet Gynecol 2004; 103:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/10\">",
"      Kozman E, Collins P, Howard A, et al. The effect of an intrauterine application of two percent lignocaine gel on pain perception during Vabra endometrial sampling: a randomised double-blind, placebo-controlled trial. BJOG 2001; 108:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/11\">",
"      Edelman A, Nichols MD, Leclair C, et al. Intrauterine lidocaine infusion for pain management in first-trimester abortions. Obstet Gynecol 2004; 103:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/12\">",
"      Costello MF, Horrowitz S, Steigrad S, et al. Transcervical intrauterine topical local anesthetic at hysterosalpingography: a prospective, randomized, double-blind, placebo-controlled trial. Fertil Steril 2002; 78:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/13\">",
"      Chen SS, Lee L. Reappraisal of endocervical curettage in predicting cervical involvement by endometrial carcinoma. J Reprod Med 1986; 31:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/14\">",
"      Hulka JF, Lefler HT Jr, Anglone A, Lachenbruch PA. A new electronic force monitor to measure factors influencing cervical dilation for vacuum curettage. Am J Obstet Gynecol 1974; 120:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/15\">",
"      Molin A. Risk of damage to the cervix by dilatation for first-trimester-induced abortion by suction aspiration. Gynecol Obstet Invest 1993; 35:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/16\">",
"      Hunter RE, Reuter K, Kopin E. Use of ultrasonography in the difficult postmenopausal dilation and curettage. Obstet Gynecol 1989; 73:813.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson, JD, Rock, J. Operative Gynecology. JB Lippincott, Philadelphia, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/18\">",
"      Gebauer G, Hafner A, Siebzehnr&uuml;bl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 2001; 184:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/19\">",
"      Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975; 45:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/20\">",
"      Ben-Baruch G, Menczer J, Shalev J, et al. Uterine perforation during curettage: perforation rates and postperforation management. Isr J Med Sci 1980; 16:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/21\">",
"      Hefler L, Lemach A, Seebacher V, et al. The intraoperative complication rate of nonobstetric dilation and curettage. Obstet Gynecol 2009; 113:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/22\">",
"      Lowensohn RI, Hibbard LT. Laceration of the ascending branch of the uterine artery: a complication of therapeutic abortion. Am J Obstet Gynecol 1974; 118:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/23\">",
"      Sacks PC, Tchabo JG. Incidence of bacteremia at dilation and curettage. J Reprod Med 1992; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/24\">",
"      Park TK, Flock M, Schulz KF, Grimes DA. Preventing febrile complications of suction curettage abortion. Am J Obstet Gynecol 1985; 152:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/25\">",
"      Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1990; 264:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/26\">",
"      Valle RF, Sciarra JJ. Intrauterine adhesions: hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol 1988; 158:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/27\">",
"      Broome JD, Vancaillie TG. Fluoroscopically guided hysteroscopic division of adhesions in severe Asherman syndrome. Obstet Gynecol 1999; 93:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/28\">",
"      Twiggs LB, Phillips GL. Documentation of subclinical trophoblastic embolization with invasive cardiac monitoring in a woman with a molar pregnancy. A case report. J Reprod Med 1986; 31:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35480/abstract/29\">",
"      Cohle SD, Petty CS. Sudden death caused by embolization of trophoblast from hydatidiform mole. J Forensic Sci 1985; 30:1279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3273 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35480=[""].join("\n");
var outline_f34_41_35480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Therapeutic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tenaculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endocervical curettage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sounding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cervical dilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complicated cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Curettage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Curettes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Sharp curettage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Suction curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cervical injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Trophoblastic embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POSTOPERATIVE CARE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3273\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3273|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/4/31808\" title=\"figure 1\">",
"      Auvard weighted speculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/36/39493\" title=\"figure 2\">",
"      How to dilate cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/17/30997\" title=\"figure 3\">",
"      Sharp curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3273|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/29/34261\" title=\"picture 1\">",
"      Pipelle and Vabra instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/32/16900\" title=\"picture 2\">",
"      Vaginal retractors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/3/16432\" title=\"picture 3\">",
"      Types of tenaculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/8/26753\" title=\"picture 4\">",
"      Polyp forceps-Kevorkian curette",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/57/16277\" title=\"picture 5\">",
"      Cervical dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/63/40945\" title=\"picture 6\">",
"      Sharp curettes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/26/27045\" title=\"picture 7\">",
"      Suction curettes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=related_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11305?source=related_link\">",
"      Managing an episode of severe or prolonged uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/24/8578?source=related_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/33/29202?source=related_link\">",
"      Patient information: Dilation and curettage (D and C) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20499?source=related_link\">",
"      Pelvic examination under anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38440?source=related_link\">",
"      Surgical instruments for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35481="Ethinyl estradiol, drospirenone, and levomefolate: Drug information";
var content_f34_41_35481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol, drospirenone, and levomefolate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/55/22390?source=see_link\">",
"    see \"Ethinyl estradiol, drospirenone, and levomefolate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10882084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10968127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Beyaz&trade;;",
"     </li>",
"     <li>",
"      Safyral&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10839772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10883136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne, PMDD:",
"     </b>",
"     Oral: Females: (Beyaz&trade;): Refer to dosing for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Contraception:",
"     </b>",
"     Oral: Females: (Beyaz&trade;, Safyral&trade;): Dosage is 1 tablet daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Beyaz&trade;: One pink tablet daily for 24 consecutive days, then one light orange tablet daily on days 25-28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Safyral&trade;: One orange tablet daily for 21 consecutive days, then one light orange tablet daily on days 22-28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose should be taken at the same time each day, either after the evening meal or at bedtime. Dosing may be started on the first day of menstrual period (Day 1 starter) or on the first Sunday after the onset of the menstrual period (Sunday starter).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Day 1 starter: Dose starts on first day of menstrual cycle taking 1 tablet daily. If first dose is taken later than the first day of the menstrual cycle,",
"     <b>",
"      an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sunday starter: Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Switching from a different contraceptive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral contraceptive: Start on the same day that a new pack of the previous oral contraceptive would have been taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal patch, vaginal ring, injection: Start on the day the next dose would have been due",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     IUD or implant: Start on the day of removal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Use after childbirth (in women who are not breast-feeding) or after second trimester abortion: Therapy may be started &ge;4 weeks postpartum. Pregnancy should be ruled out prior to treatment if menstrual periods have not restarted and an additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Missed doses:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, rule out pregnancy and discontinue if pregnancy is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If doses have been missed during the first 3 weeks or if active tablets (pink tablets) were started later than as directed and the menstrual period is missed, pregnancy should be ruled out prior to continuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Missed doses (monophasic formulations)",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time:",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Day 1 starter: Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Sunday starter: Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Any number of doses missed in week 4: Throw away the pills that were missed. Continue taking one pill each day until pack is empty; no back-up method of contraception is needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10883137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Females: Children &ge;14 years: Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Contraception, PMDD:",
"     </b>",
"     Females: Oral: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10883139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10883138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic disease. Exposure to drospirenone is ~3 times higher with moderate liver impairment; information not available for severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10883151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beyaz&trade;: Ethinyl estradiol 0.02 mg, drospirenone 3 mg, and levomefolate calcium 0.451 mg [24 pink tablets] and levomefolate calcium 0.451 mg [4 light orange tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Safyral&trade;: Ethinyl estradiol 0.03 mg, drospirenone 3 mg, and levomefolate calcium 0.451 mg [21 orange tablets] and levomefolate calcium 0.451 mg [7 light orange tablets] (28s)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10883145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food, but must be taken at the same time each day, preferably after the evening meal or at bedtime. If severe vomiting or diarrhea occurs, additional contraception (nonhormonal) should be used. If vomiting occurs within 3-4 hours of dosing, consider the dose to be missed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10839774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; treatment of premenstrual dysphoric disorder (PMDD); treatment of acne; folate supplementation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10882085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10839767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Beyaz&trade; may be confused with Yaz&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10883104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported with Beyaz&trade;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache/migraine (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Menstrual irregularities (4% to 25%, including menorrhagia, metrorrhagia, spotting, vaginal hemorrhage), breast pain/tenderness (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea/vomiting (4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (4%), irritability (3%), affect lability (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Libido decreased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: Cervical dysplasia, cervix carcinoma stage 0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For additional adverse events and postmarketing reports, refer to the Ethinyl Estradiol and Drospirenone (Yasmin&reg;, Yaz&reg;) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10882089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adrenal insufficiency, breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, renal impairment, undiagnosed abnormal uterine bleeding. Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), hypercoagulopathies (inherited or acquired), headaches with focal neurological symptoms, hypertension (uncontrolled), migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), women &gt;35 years of age who smoke.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10882090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Estrogens may induce or exacerbate symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloasma: Use caution with a history of chloasma gravidarum; women with a tendency to chloasma should avoid sun and ultraviolet radiation exposure during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Cholestasis may occur in women with a history of pregnancy-related or previous oral contraceptive-related cholestasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Drospirenone has antimineralocorticoid activity that may lead to hyperkalemia in patients with renal insufficiency, hepatic dysfunction, or adrenal insufficiency; use caution with medications that may increase serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Progestins may be associated with decreased HDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Contraceptives may increase the risk of thromboembolism. Discontinue if an arterial or deep venous thrombotic event occurs. Risk may be greater with contraceptives containing drospirenone. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with hypercoagulopathies (inherited or acquired).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Unscheduled bleeding /spotting may occur within the first 3 months of use. Presentation of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction or stroke. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use another form of contraception. Monitor women with well-controlled hypertension and discontinue if blood pressure rises significantly. Use is contraindicated with uncontrolled hypertension or hypertension with vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Steroid hormones are poorly metabolized in patients with hepatic dysfunction. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe, or persistent headaches. Use is contraindicated in women with headaches with focal neurological symptoms or migraine headaches if &gt;35 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acne use: For use only in females &ge;14 years of age who have reached menarche, who also desire combination hormonal contraceptive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Inform patients that oral contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). Drospirenone also can caused an increase in plasma renin activity and plasma aldosterone. Folates may mask vitamin B12 deficiency. The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PMDD use: For use only in females who desire combination hormonal contraceptive therapy; use for more than 3 menstrual cycles has not been evaluated. Has not been evaluated for the treatment of premenstrual syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10890709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Drospirenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Levomefolate may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Levomefolate may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Levomefolate may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Drospirenone may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Levomefolate may decrease serum concentrations of the active metabolite(s) of Primidone. Levomefolate may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Levomefolate may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10883101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: CNS effects of caffeine may be enhanced if oral contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol plasma concentrations; clinical implications are unclear. Food decreases the maximum plasma concentrations of drospirenone and ethinyl estradiol by ~40%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10882086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of oral contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. The addition of levomefolate in this product is intended to decrease the risk of neural tube defects if pregnancy inadvertently occurs during therapy or shortly after discontinuation. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC,  2011). The manufacturer states that combination hormonal contraceptives should not be started until &ge;4 weeks after delivery in women who choose not to breastfeed, or &ge;4 weeks after a second trimester abortion or miscarriage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10882087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10882088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of drospirenone excreted in breast milk is ~0.02%, resulting in a maximum of ~3 mcg/day drospirenone to the infant. Jaundice and breast enlargement in the nursing infant have been reported following the use of other oral contraceptives. In addition, may decrease the quality and quantity of breast milk. Other forms of contraception are recommended while breast-feeding (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10883144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at the same time each day; may be taken with or without a meal. Consider other sources of folic acid and ensure supplementation continues once therapy is discontinued. The RDA for folate in women 14&ndash;50 years of age is 400 mcg/day of dietary folate equivalents. The USPSTF recommends that all women of reproductive potential should take a supplement containing folic acid 400-800 mcg/day in order to decrease the risk of neural tube defects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Beyaz Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.02-0.451 mg (28): $102.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Safyral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.03-0.451 mg (28): $102.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10883147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; serum potassium in high-risk patients and those on medications with potassium-retaining properties. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10883124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination oral contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, oral contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Oral contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10883126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Drospirenone: ~4 L/kg; Ethinyl estradiol: ~4-5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Drospirenone: Serum proteins (excluding sex hormone-binding globulin and corticosteroid-binding globulin): ~97%; Ethinyl estradiol: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Drospirenone: To inactive metabolites, minor metabolism hepatically via CYP3A4; Ethinyl estradiol: Hepatic via CYP3A4; forms metabolites; undergoes first-pass metabolism and enterohepatic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Drospirenone: ~76%; Ethinyl estradiol: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: Drospirenone: ~31 hours; Ethinyl estradiol: ~24 hours; levomefolate calcium: ~4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Drospirenone, ethinyl estradiol: 1-2 hours; Levomefolate calcium: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Drospirenone, ethinyl estradiol, levomefolate calcium: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/15105794/pubmed\" id=\"15105794\" target=\"_blank\">",
"        15105794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jick SS and Hernandez RK, \"Risk of Non-Fatal Venous Thromboembolism in Women Using Oral Contraceptives Containing Drospirenone Compared With Women Using Oral Contraceptives Containing Levonorgestrel: Case-Control Study Using United States Claims Data,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2011, 349:d2151.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/21511805/pubmed\" id=\"21511805\" target=\"_blank\">",
"        21511805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      </i>",
"      <sub>",
"       6",
"      </sub>",
"      <i>",
"       , Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin and Choline",
"      </i>",
"      , Washington, DC: National Academy Press, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Preventive Services Task Force, &ldquo;Folic Acid for the Prevention of Neural Tube Defects: U.S. Preventive Services Task Force Recommendation Statement,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(9):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/19414842/pubmed\" id=\"19414842\" target=\"_blank\">",
"        19414842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/41/35481/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16080 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-189.41.172.26-7516A9B4AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35481=[""].join("\n");
var outline_f34_41_35481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882084\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10968127\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839772\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883136\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883137\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883139\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883138\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883145\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839774\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882085\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10839767\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883104\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882089\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882090\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299298\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10890709\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883101\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882086\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882087\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882088\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883144\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322868\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883147\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883124\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10883126\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/55/22390?source=related_link\">",
"      Ethinyl estradiol, drospirenone, and levomefolate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35482="Anesthesia for the obese patient undergoing non-cardiac surgery";
var content_f34_41_35482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anesthesia for the obese patient undergoing non-cardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Roman Schumann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/41/35482/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/41/35482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1086370192\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, it is estimated that a billion adults are overweight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, more than 75 million American adults are obese and it is not uncommon for the anesthesiologist to administer anesthesia to patients who meet the criteria for morbid obesity (ie, body mass index &gt;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for routine elective surgery or surgery for weight loss. The increase in the number of bariatric procedures over the past decade has contributed to interest in this area of anesthesia and improved knowledge and experience in the perioperative management of obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/2\">",
"     2",
"    </a>",
"    ]. However, perioperative care guidelines are predominantly based upon retrospective review or expert opinion. Best practice policies based upon the results of randomized trials that show direct improvement in clinically important outcome measures are needed. &nbsp;",
"   </p>",
"   <p>",
"    The perioperative anesthetic management of the obese patient will be reviewed. Anesthetic principles and general anesthetic management are discussed in separate topic reviews. The surgical management of severe obesity and its complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20091528\">",
"    <span class=\"h1\">",
"     OBESITY-RELATED PHYSIOLOGIC CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative morbidity related to obesity may be related to physiologic changes that impact the delivery of anesthesia and perioperative analgesia, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control of the airway is potentially hampered by reduced neck mobility and altered oropharyngeal anatomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. The pharyngeal space is narrowed due to increased soft tissue within the confines of the maxilla-mandibular space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H705031\">",
"       'Airway management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Altered respiratory mechanics and decreased chest wall compliance interfere with oxygenation and ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/7\">",
"       7",
"      </a>",
"      ]. Severe obesity causes a reduction in functional residual capacity (FRC) and expiratory reserve volume, particularly in the supine position. The work of breathing is increased because of decreased chest wall compliance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/8\">",
"       8",
"      </a>",
"      ]. In obese patients, intraoperative and postoperative tissue oxygen tension may be significantly reduced compared with baseline, even with supplemental oxygen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H35#H35\">",
"       \"Diseases of the chest wall\", section on 'Obesity'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H705031\">",
"       'Airway management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The factors that determine drug distribution into the tissues include plasma protein binding, regional blood flow and body composition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/10\">",
"       10",
"      </a>",
"      ]. Some or all of these components may be altered in severe obesity including the volume of distribution for specific drugs. The pharmacodynamics and pharmacokinetics of many medications are unknown for severely obese individuals. Initial dosing may be based on total body weight (TBW), lean body weight (LBW, similar to lean body mass) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/21/29009?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/26/29089?source=see_link\">",
"       calculator 2",
"      </a>",
"      ), or ideal body weight (IBW) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=see_link\">",
"       calculator 3",
"      </a>",
"      ) depending upon the agent chosen and presence of comorbidities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. When drug pharmacokinetic and pharmacodynamic parameters are unknown, initial dosing in obese patients should begin based upon LBW (",
"      <a class=\"graphic graphic_table graphicRef66098 \" href=\"mobipreview.htm?17/27/17852\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086370207\">",
"    <span class=\"h1\">",
"     ANESTHESIA CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For major surgery in the severely obese patient, the preoperative evaluation should include consultation with an anesthesiologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Major surgery is any procedure that accesses the chest or abdominal cavities, including minimally invasive bariatric surgery. However, clinical judgment taking into account the patient&rsquo;s degree of obesity, apparent comorbidities, type of surgery and anesthesia, and postoperative needs may indicate the need for anesthesia consultation for any type of surgery.",
"   </p>",
"   <p>",
"    A history and physical examination and selective preoperative testing can identify patients with silent comorbidities and those at risk for complications due to possible underlying obstructive sleep apnea during and following anesthesia (",
"    <a class=\"graphic graphic_table graphicRef55763 graphicRef70982 \" href=\"mobipreview.htm?39/27/40381\">",
"     table 2A-B",
"    </a>",
"    ). Other advantages of anesthesia consultation include improved patient education and early identification of airway and vascular access issues. With appropriate preoperative management, airway complications and the need to cancel cases due to previously undetected or inadequately controlled medical conditions can be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are presently no data in the literature providing clear, evidence-based guidance regarding the need and appropriateness of an advance preoperative anesthesiology consultation based on obesity alone. Likewise, it has not been determined when such consultation is definitively not needed. For example, advance anesthesia consultation is unlikely to be necessary in a younger patient (&lt;50 years) with a BMI of &lt;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and without obvious comorbidities who will undergo outpatient ophthalmologic surgery. On the other hand, for the same procedure, an anesthesiology consultation should be considered in the severely obese older patient who is unable to lie flat or who has obstructive sleep apnea, hypertension or diabetes, or a coronary stent. When in doubt, at a minimum, the preoperative charts of severely obese patients should be screened by an anesthesiologist ahead of time to determine the need for advance preoperative consultation. However, data to support such an approach are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086370214\">",
"    <span class=\"h2\">",
"     Evaluation of comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased body mass index (BMI) (",
"    <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"     calculator 4",
"    </a>",
"    ) in the absence of comorbidities, also termed &lsquo;simple obesity&rsquo;, is not associated with adverse postoperative outcomes in patients undergoing noncardiac surgery, with the exception of venous thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H9#H9\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H50#H50\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Cardiovascular risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity has been associated with lowered morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The &ldquo;obesity paradox&rdquo; identified in many studies is likely due to the presence of two distinct populations of obese patients, those without and those with metabolic markers of obesity or the metabolic syndrome. Metabolic syndrome is characterized by central obesity, hypertension, hyperglycemia, dyslipidemia, and prothrombotic and proinflammatory states. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The apparent protective effect of obesity may be due to the large number of metabolically healthy but obese patients included in cohorts of obese patients being studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/18\">",
"     18",
"    </a>",
"    ]. Compared with normal patients or obese patients without metabolic syndrome, obese patients with metabolic syndrome undergoing noncardiac surgery",
"    <strong>",
"     do",
"    </strong>",
"    appear to be at increased risk for perioperative morbidity and mortality and the degree of risk correlates with BMI.",
"   </p>",
"   <p>",
"    A large National Surgical Quality Improvement Program (NSQIP) database study that included more than 310,000 patients undergoing non-cardiac surgery, compared normal weight patients with obese patients who did or did not have metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/18\">",
"     18",
"    </a>",
"    ]. There were no significant differences in the risk for perioperative morbidity or mortality between normal weight and metabolically healthy, obese patients. In this study, the following classifications of BMI",
"    <span class=\"nowrap\">",
"     [kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </span>",
"    were used: Overweight: 25 to 29.9; Obese: 30 to 39.9; Morbidly obese: 40 to 49.9; Super Obese: &gt;50.",
"   </p>",
"   <p>",
"    Standardized classification of BMI endorsed by the National Institute of Health (NIH) and World Health Organization (WHO) are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link&amp;anchor=H7#H7\">",
"     \"Screening for and clinical evaluation of obesity in adults\", section on 'Classification of BMI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For obese patients with metabolic syndrome, the adjusted odds ratios (AOR) for adverse cardiac events compared with normal-weight patients were as follows: obese, 1.7 (95% CI 1.40-2.07), morbidly obese, 2.0 (95% CI 1.48-2.73), and super obese 2.66 (95% CI 1.68-4.19). The risks for acute kidney injury were obese 3.30 (95% CI 2.75-3.94), morbidly obese 5.0, (95% CI 3.87-6.49), and super obese 7.29 (95% CI 5.27-10.1).",
"   </p>",
"   <p>",
"    Thus, it is important to evaluate the patient preoperatively for metabolic syndrome and its associated conditions including cardiovascular disease, hypertension, type 2 diabetes mellitus and kidney disease. These conditions and obstructive sleep apnea (OSA) may be undiagnosed prior to consideration for surgery, particularly if the patient has a poor record of engaged health maintenance, including regular primary care visits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of silent cardiac ischemia may approach 10 percent for those with two or more major coronary risk factors, including obesity, smoking, family history of heart disease, age over 45 years, diabetes, hypertension, and hypercholesterolemia. Such patients may be identified by appropriate cardiac evaluation including EKG and stress tests as indicated.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42135?source=see_link&amp;anchor=H4#H4\">",
"       \"Silent myocardial ischemia: Epidemiology and pathogenesis\", section on 'Asymptomatic patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all ages, the risk of type 2 diabetes increases with increasing body weight. Abnormal glucose metabolism can be documented years before the onset of overt diabetes. Determination of HbA1C may detect these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=see_link&amp;anchor=H5#H5\">",
"       \"Risk factors for type 2 diabetes mellitus\", section on 'Obesity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of chronic kidney disease is increased (relative risk 2.3, 95% CI 1.1-4.9) in patients with severe obesity (BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      compared with normal weight persons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/19\">",
"       19",
"      </a>",
"      ]. This risk appears to be largely mediated by the presence of diabetes and hypertension. Standard preoperative laboratory testing including the creatinine value within a reasonable time frame prior to surgery (eg, six months) may assist recognition of these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H30#H30\">",
"       \"Health hazards associated with obesity in adults\", section on 'Kidney disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28966?source=see_link&amp;anchor=H2666200#H2666200\">",
"       \"Screening for chronic kidney disease\", section on 'Methods of screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea is the predominant form of sleep disordered breathing in severely obese patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/20\">",
"       20",
"      </a>",
"      ]. Obstructive sleep apnea occurs when airflow is absent or nearly absent due to upper airway obstruction, but ventilatory effort is normal. Obstructive sleep apnea often goes undiagnosed and the preoperative history and physical examination should specifically assess for its signs and symptoms (",
"      <a class=\"graphic graphic_table graphicRef81751 graphicRef59695 \" href=\"mobipreview.htm?0/6/105\">",
"       table 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1065684\">",
"    <span class=\"h2\">",
"     Preoperative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific preoperative testing should be decided on an individual basis depending upon the nature of the planned surgical procedure and the obese patient&rsquo;s medical comorbidities following the published practice advisory of the American Society of Anesthesiologists (ASA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The preoperative medical evaluation of the obese patient without cardiovascular risk factors or medical comorbidities is similar to normal-weight patients being evaluated for surgery and is discussed in detail elsewhere. Highlights of the preoperative evaluation as it pertains to the obese patient in general are summarized below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    We prefer to obtain basic preoperative laboratory tests for all obese patients including a recent (within six months) hematocrit, glucose, blood urea nitrogen (BUN) and creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11\">",
"     11",
"    </a>",
"    ]. Other blood work (eg, HbA1C), noninvasive cardiac testing, chest radiograph and pulmonary function tests should be obtained selectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H2#H2\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Rationale for selective testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Heart Association (AHA) 2009 scientific advisory on cardiovascular evaluation and management of severely obese patients (BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      undergoing surgery states that an electrocardiogram is reasonable in obese patients with at least one risk factor for coronary heart disease (diabetes, smoking, hypertension, or hyperlipidemia) or poor exercise tolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/24\">",
"       24",
"      </a>",
"      ]. &nbsp;Additional testing is selectively obtained based upon the electrocardiogram results. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H20#H20\">",
"       \"Preoperative medical evaluation of the healthy patient\", section on 'Electrocardiogram'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American College of Physicians (ACP) recommends chest radiograph for patients with cardiopulmonary disease, and patients older than 50 years of age undergoing abdominal aortic aneurysm surgery, or upper abdominal or thoracic surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/25\">",
"       25",
"      </a>",
"      ]. Posteroanterior and lateral chest x-ray is also suggested by the AHA for patients with severe obesity (BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/24\">",
"       24",
"      </a>",
"      ]. However, in the absence of a medical history or clinical symptoms (eg, dyspnea, cough, fever) that might suggest cardiopulmonary disease (eg, pneumonia, heart failure), findings on preoperative chest radiograph have",
"      <strong>",
"       not",
"      </strong>",
"      been found to affect perioperative outcomes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link&amp;anchor=H21#H21\">",
"       \"Preoperative medical evaluation of the healthy patient\", section on 'Chest radiograph'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mandatory polysomnography (ie, sleep study) has been proposed for patients undergoing bariatric surgery, but it is unclear if information gained from testing is associated with improved outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/26\">",
"       26",
"      </a>",
"      ]. Routine preoperative polysomnography is",
"      <strong>",
"       not",
"      </strong>",
"      advocated for all patients with obstructive sleep apnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"       27",
"      </a>",
"      ]. The decision to pursue testing primarily depends upon the patient&rsquo;s history, physical examination, and type of surgery planned. The preoperative evaluation of the patient with obstructive sleep apnea is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Rather than mandatory polysomnography, another approach involves the use of clinical questionnaires or prediction scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. The STOP questionnaire and the modified version called the STOP-Bang questionnaire are practical for clinicians and have emerged as frequently-used and cost-effective approaches to identify patients with obstructive sleep apnea. STOP assesses Snoring, Tiredness, Observed apnea and high blood Pressure, and Bang adds BMI, age, neck circumference and gender. In a systematic review of preoperative questionnaires that included 10 studies with a total of 1484 patients, both the STOP and STOP-Bang questionnaires were found to have the best methodological quality and ease of use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/29\">",
"       29",
"      </a>",
"      ]. In a study of 2467 adult patients without a prior diagnosis of sleep apnea, the sensitivities of the STOP questionnaire in diagnosing sleep apnea were 65.6, 74.3, and 79.5 percent, using apnea-hypopnea index (AHI) (monitored polysomnography) cutoffs of &gt;5, &gt;15, and &gt;30, respectively (",
"      <a class=\"graphic graphic_table graphicRef55763 \" href=\"mobipreview.htm?10/61/11227\">",
"       table 2A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/31\">",
"       31",
"      </a>",
"      ]. When incorporating Bang, sensitivities increased to 84, 93, and 100 percent with the same AHI cutoffs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704994\">",
"    <span class=\"h2\">",
"     Preoperative counseling",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708499\">",
"    <span class=\"h3\">",
"     Positive airway pressure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese patients with a diagnosis of obstructive sleep apnea (OSA) or obesity-hypoventilation syndrome who have been using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) therapy should be instructed to adhere to their treatment regimen prior to elective surgery to maintain the benefits of treatment on their physical status. Furthermore, patients are instructed to bring their breathing equipment with them on the day of surgery for use postoperatively. (See",
"    <a class=\"local\" href=\"#H19621674\">",
"     'Respiratory care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of patients with newly diagnosed OSA as a result of preoperative evaluation and testing depends upon the severity of OSA, and risk for postoperative respiratory compromise (",
"    <a class=\"graphic graphic_table graphicRef70982 \" href=\"mobipreview.htm?21/41/22173\">",
"     table 2B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Disease spectrum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe sleep apnea derive the most benefit from preoperative therapy and the authors prefer to initiate positive airway pressure therapy for four to six weeks prior to surgery, time permitting. Many OSA-associated medical conditions will improve within such a time frame, and their preoperative treatment may reduce postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/32\">",
"     32",
"    </a>",
"    ]. Preoperative positive airway pressure therapy is associated with several physiologic benefits that improve delivery of anesthesia and overall anesthetic management. The most important of these include reduced tongue volume and increased volume of the pharyngeal space (an effect that occurs following four to six weeks of therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/33\">",
"     33",
"    </a>",
"    ], improved cardiac parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], and improved ventilatory drive in patients with obesity-hypoventilation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Positive airway pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link&amp;anchor=H15227571#H15227571\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\", section on 'Preoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086370238\">",
"    <span class=\"h3\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is an independent risk factor for postoperative pulmonary complications with significant reductions in these complications when smoking has been stopped, ideally for eight weeks. Shorter periods of smoking cessation may provide short-term benefits, such as decreased carboxyhemoglobin levels on the day of surgery, but in some patients the risk of pulmonary complications increases due to reduced mucociliary clearance of secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link&amp;anchor=H4#H4\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preoperative evaluation provides an opportunity to discuss the benefits of smoking cessation.",
"    <strong>",
"    </strong>",
"    The anesthesiologist is an important part of the multidisciplinary team responsible for advocating smoking cessation for the patient&rsquo;s and the public&rsquo;s long-term benefit. The American Society of Anesthesiologists (ASA) smoking cessation initiative task force is exploring systematic approaches that could increase the anesthesiologist&rsquo;s impact on smoking cessation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708522\">",
"    <span class=\"h3\">",
"     Ambulatory versus inpatient surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesia in the ambulatory surgery setting for obese patients is very safe. More and more, ambulatory surgery is being offered to populations with comorbidities, with many ambulatory surgery units routinely anesthetizing patients with a body mass index (BMI) &gt;30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. There are, however, no high-quality studies to guide patient or procedure selection for this operative setting in severely obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/43\">",
"     43",
"    </a>",
"    ]. Although a diagnosis of obstructive sleep apnea (OSA) is not a contraindication to ambulatory surgery, there remains an ongoing debate over what types of procedures can be safely performed in the ambulatory care setting in morbidly obese OSA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/44\">",
"     44",
"    </a>",
"    ]. A retrospective review assessed outcomes in 1780 morbidly obese patients undergoing outpatient laparoscopic gastric banding in a freestanding ambulatory surgical center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/44\">",
"     44",
"    </a>",
"    ]. No hospital admissions were required in 320 patients who had OSA and BMI of &gt;50",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    For morbidly obese patients, logistical factors are important in determining the feasibility of outpatient surgery performed at a freestanding facility. Some considerations include the immediate availability of emergency difficult airway equipment, advanced respiratory care equipment, access to laboratory and radiology facilities, and transfer agreements with external facilities. In addition, the presence of an established clinical pathway for the care of the morbidly obese patient with tailored discharge criteria is ideal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19621685\">",
"     'Discharge criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A scoring system can be used to estimate the risk of adverse perioperative outcomes in patients with OSA based upon severity of sleep apnea, the need for systemic or neuraxial opioids, site and invasiveness of the surgical procedure and type of anesthesia administered (",
"    <a class=\"graphic graphic_table graphicRef55763 graphicRef70982 \" href=\"mobipreview.htm?39/27/40381\">",
"     table 2A-B",
"    </a>",
"    ). This scoring system is based upon the ASA practice guidelines for the perioperative management of patients with obstructive sleep apnea but has not been prospectively validated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"     27",
"    </a>",
"    ]. A risk score of &gt;5 indicates a significantly increased risk for perioperative complications, and such patients are not good candidates for outpatient surgery. Additional factors for risk assessment include patient age, anatomic and physiologic abnormalities, and comorbidities. Superficial surgeries performed with local or regional anesthesia, or procedures such as lithotripsy can be performed safely on an outpatient basis in most patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27,48\">",
"     27,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708223\">",
"    <span class=\"h1\">",
"     ANESTHETIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of anesthetic technique for obese patients should be guided by the requirements of the surgical procedure, comorbidities and patient preferences. General anesthesia, regional anesthetic and sedation techniques have all been employed safely in obese patients, and no technique has been found to be superior over another with respect to important patient outcomes (eg, mortality, cardiopulmonary complications). Common goals for anesthetic management of obese patients, regardless of technique chosen, but particularly in the presence of sleep apnea, include minimizing sedation and opioid administration to decrease the risk of respiratory depression and allow rapid emergence from anesthetic or sedative effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086370269\">",
"    <span class=\"h2\">",
"     Inhalational agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled potent volatile anesthetic agents are the most frequently used drugs for maintenance of general anesthesia, including for obese patients. Minimal alveolar concentration (MAC) is a measure of drug potency and is affected by many factors, including age, medications, and patient-specific factors including body weight. Both MAC and the solubility of inhalational agents in the blood and tissues differ among the various agents. Those with low solubility have a rapid onset, and rapid offset of effect which may allow for faster recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link&amp;anchor=H14#H14\">",
"     \"Awareness with recall following general anesthesia\", section on 'Minimum alveolar concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potent volatile anesthetic agents including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    have been used safely for the maintenance of general anesthesia in severely obese patients. In the available studies, no significant differences between the agents have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/50\">",
"     50",
"    </a>",
"    ]. Several small trials have compared sevoflurane to desflurane in morbidly obese patients focusing on emergence and recovery characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Desflurane should facilitate the speed of emergence and the reestablishment of airway reflexes due to its low blood solubility. In two of these trials, faster emergence and recovery was found for desflurane, but the clinical difference was small and it is unclear whether any identified differences would impact patient safety or other outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. A retrospective study compared morbidly obese with super obese patients (BMI &gt;50",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and found no difference in outcomes and hospital course following general anesthesia with desflurane, sevoflurane or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    infusion for weight-loss surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    has frequently been used to complement potent volatile agents. Because of its physicochemical properties, it is able to quickly diffuse into and distend gas filled compartments, such as the bowel. A study comparing the use of inhalational agents with or without nitrous oxide during laparoscopic bariatric surgery found that the addition of nitrous oxide did not cause noticeable bowel distention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/56\">",
"     56",
"    </a>",
"    ]. However, some obese patients may not tolerate the decreased inspired oxygen concentration that accompanies the use of nitrous oxide, and the anesthetic may need to be adjusted accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705003\">",
"    <span class=\"h2\">",
"     Neuraxial anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial anesthetic techniques (spinal, epidural) minimally affect respiratory drive and sleep patterns and are safe and appropriate choices for obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, sympathetic blockade can spread to higher levels in obese compared with normal weight patients. For spinal blockade, this is thought to be due to a relatively smaller spinal compartment. Compression of the spinal compartment by an epidural space that is expanded from increased epidural adipose tissue facilitates spread of intrathecally administered local anesthetics. The reasons for augmented sympathetic epidural blockade in this population are unclear.",
"   </p>",
"   <p>",
"    High regional blocks may result in comparatively greater respiratory impairment in obese patients due to their altered respiratory mechanics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/59\">",
"     59",
"    </a>",
"    ]. Also, regional techniques may technically be more difficult to perform in obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/10,59-61\">",
"     10,59-61",
"    </a>",
"    ]. The risks and benefits of adding opioid to local anesthetic solutions for neuraxial anesthesia and analgesia in patients with OSA need to be carefully appraised to minimize the risk for delayed respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27,62\">",
"     27,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidural catheters can be maintained postoperatively for analgesia. Postoperative pain management with epidural catheters improves respiratory function in obese individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of postoperative pain\", section on 'Morbid obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 84 obese patients that included obese subjects undergoing midline laparotomy, postoperative vital capacity and FEV1 decreased less and returned to baseline faster in patients with epidural catheters compared with patients receiving systemic opioids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/63\">",
"       63",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In a randomized trial of 915 high-risk patients that included patients who were morbidly obese, the incidence of respiratory failure was significantly lower in the epidural group compared with patients who received standard analgesic therapy (23 versus 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 60 obese patients were randomly assigned to general anesthesia with or without thoracic epidural analgesia (TEA). Tracheal extubation time and intensive care unit stay were significantly less in patients who had TEA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702495\">",
"    <span class=\"h2\">",
"     Peripheral nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve blocks can also be used safely in morbidly obese patients and are effective in minimizing or eliminating the need for opioids. A variety of peripheral nerve blocks have been used in the obese population including interscalene block, supraclavicular block, and axillary block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obese patients",
"    <strong>",
"    </strong>",
"    with BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    were 1.62 times more likely to have a failed block and the rate of acute complications was higher in obese patients (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    compared with normal weight patients in one retrospective study of 6920 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ultrasound-guided regional techniques has been shown to reduce the number of attempts and time needed for peripheral block placement in normal weight patients. There are no trials comparing traditional and ultrasound-guided regional techniques in obese patients. In a retrospective study of 70 patients, the success rate of ultrasound-guided interscalene nerve blocks was similar in obese and nonobese individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/67\">",
"     67",
"    </a>",
"    ]. The technical aspects of ultrasound-guided peripheral nerve block are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of peripheral nerve blocks\", section on 'Ultrasound guidance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705010\">",
"    <span class=\"h2\">",
"     Intravenous anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous anaesthetic agents and adjuncts can also be used safely in obese patients to provide total intravenous anesthesia (TIVA), or to supplement inhalational or regional anesthetic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. For patients with obstructive sleep apnea (OSA) under light to moderate sedation, carbon dioxide levels are continuously monitored, and an oral airway appliance (and potentially continuous positive airway pressure) used to prevent airway collapse and hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"     27",
"    </a>",
"    ]. For deep sedation, a secure intubated airway is preferable in most cases.",
"   </p>",
"   <p>",
"    Dosing of medications used for intravenous anesthesia (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , opioids) is based upon total body weight (TBW), ideal body weight (IBW), or lean body weight (LBW) according to gender (for adult males (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/21/29009?source=see_link\">",
"     calculator 1",
"    </a>",
"    ); for adult females (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/26/29089?source=see_link\">",
"     calculator 2",
"    </a>",
"    )) depending upon the agent (",
"    <a class=\"graphic graphic_table graphicRef63370 \" href=\"mobipreview.htm?18/46/19181\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/72\">",
"     72",
"    </a>",
"    ]. However, clinical judgment and titration to clinical effect will be the guiding principles of dosing. (See",
"    <a class=\"local\" href=\"#H702538\">",
"     'Monitoring'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H9#H9\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Weight based dosing of medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is initially based upon lean body weight (LBW) to achieve an acceptable level of anesthesia. Propofol accumulation does not appear to occur to a significant degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/73\">",
"     73",
"    </a>",
"    ]. In contrast, opioid dosing is variable with the shorter-acting agents based upon IBW or LBW (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    ), while others can initially be based upon LBW or TBW (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. For the ultrashort-acting agent remifentanil, we suggest initially dosing according to IBW and titrating to clinical effect. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/76-84\">",
"     76-84",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The alpha-2 agonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    , are adjuncts to anesthesia that can reduce intraoperative as well as postoperative opioid requirements. Given the high prevalence of obstructive sleep apnea in the morbidly obese population, minimization of opioid use and therefore its sedative effects is desirable. Unless medically or surgically contraindicated, alpha-2 agonists can be used as a part of a multimodal anesthetic regimen. Further studies are needed to determine optimal perioperative dosing and safety in obese surgical patients. (See",
"    <a class=\"local\" href=\"#H19621384\">",
"     'Multimodal analgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small randomized trial, preoperative oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      administered to obese patients with obstructive sleep apnea at a dose of 2",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      on the evening before, and again two hours prior to surgery reduced anesthetic requirements and intraoperative and postoperative opioid requirements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In three additional trials evaluating bariatric patients, intraoperative intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      similarly decreased anesthetic and opioid requirements, decreased postoperative antiemetic requirements, and shortened stay in the post-anesthesia care unit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/86-88\">",
"       86-88",
"      </a>",
"      ]. At least one case report describes opioid-free intraoperative management in an extremely obese patient using perioperative dexmedetomidine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19621584\">",
"    <span class=\"h1\">",
"     ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;General considerations for the management of postoperative pain are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19621384\">",
"    <span class=\"h2\">",
"     Multimodal analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multimodal approach to pain management reduces the risk for respiratory depression and also reduces opioid-related side effects (eg, nausea, pruritus, delayed bowel function). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link&amp;anchor=H4721198#H4721198\">",
"     \"Pain control in the critically ill adult patient\", section on 'Opioid side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In severely obese patients, multimodal analgesia should be used whenever possible, using potent non-steroidal anti-inflammatory analgesics (NSAIDs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    , along with local anesthetic wound infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/10,12,27,90-93\">",
"     10,12,27,90-93",
"    </a>",
"    ]. Additional agents being investigated to further augment multimodal analgesia include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and alpha-2 agonists, although no clear regimens have evolved yet. When patient-controlled analgesia (PCA) is used for severely obese patients with obstructive sleep apnea (OSA), the American Society of Anesthesiologists (ASA) suggests avoiding continuous infusion, unless PCA is being used for the opioid-tolerant patient who has a basal requirement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Several observational studies and three trials support the opioid-sparing effect of multimodal postoperative pain management strategies in severely obese patients; however, the optimal timing and dosing and specific protocols have yet to be determined in this population of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/91-95\">",
"     91-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study of 20 severely obese patients undergoing open gastric bypass surgery, patients were randomly assigned to receive preoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      (30 mg, intravenous) plus incisional infiltration of a local anesthetic mixture (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      ) or neither of these measures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/94\">",
"       94",
"      </a>",
"      ]. The postoperative analgesic requirements were 40 percent lower in the treated group.",
"     </li>",
"     <li>",
"      Another trial of 114 patients undergoing open gastric bypass surgery compared multimodal therapy using wound infiltration with local anesthetic plus patient-controlled opioid analgesia, thoracic epidural analgesia, or patient-controlled opioid analgesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/95\">",
"       95",
"      </a>",
"      ]. Pain scores were similar for the multimodal analgesia and thoracic epidural analgesia groups but lower compared with the group that received only patient-controlled opioid analgesia.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 50 patients undergoing bariatric surgery to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      plus an infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      before anesthetic induction, or no pre-treatment. The treated group had significantly lower anesthetic requirements, faster time to extubation (15 versus 28 minutes), lower total",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      dose (138 versus 252 mg), and lower pain scores compared with control patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19621431\">",
"    <span class=\"h2\">",
"     Alternative analgesic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary strategies, including transcutaneous electrical nerve stimulation and acupuncture, can be used to supplement pharmacologic therapy to treat pain, further reducing opioid requirements. These modalities are considered to be virtually risk free. Transcutaneous electrical nerve stimulation (TENS) uses a small battery-operated device to provide continuous electrical impulses via surface electrodes, with the goal of providing symptomatic relief by modifying pain perception. Acupuncture consists of a family of procedures used to stimulate anatomical points with the goal of reducing pain. A systematic review of the literature evaluating these alternative analgesic therapies for postoperative pain found many high-quality studies documenting a positive effect for both modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/96\">",
"     96",
"    </a>",
"    ]. However, these strategies have not been specifically explored for the severely obese patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702530\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705031\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotracheal intubation of the severely obese patient can be difficult, even for an experienced anesthesiologist, due to anatomic oropharyngeal changes that compromise laryngoscopic visualization. (See",
"    <a class=\"local\" href=\"#H20091528\">",
"     'Obesity-related physiologic changes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A ramped position is preferred for intubation and extubation and is optimal in the event of reintubation (",
"    <a class=\"graphic graphic_picture graphicRef72755 \" href=\"mobipreview.htm?20/50/21285\">",
"     picture 1",
"    </a>",
"    ). In one study of morbidly obese patients undergoing bariatric surgery in the \"ramped position,\" there was no relationship between the presence and severity of obstructive sleep apnea, body mass index or neck circumference and difficulty of intubation or laryngoscopy grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/97\">",
"     97",
"    </a>",
"    ]. Only a Mallampati score of 3 or 4 or male gender predicted difficult intubation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link&amp;anchor=H8#H8\">",
"     \"The difficult airway in adults\", section on 'The LEMON&copy; approach to difficult airway assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although trials evaluating the significance of a team approach to the potential difficult airway management in this patient population are lacking, an additional anesthesia clinician, the surgeon and the circulating nurse should be present during induction and emergence from general anesthesia to assist with any unforeseen airway crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11\">",
"     11",
"    </a>",
"    ]. Strategies for intubating the obese patient and airway management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20329?source=see_link\">",
"     \"Emergency airway management in the morbidly obese patient\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19621674\">",
"    <span class=\"h2\">",
"     Respiratory care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidly obese patients are at risk for adverse intraoperative and postoperative respiratory events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Morbid obesity results in a restrictive pulmonary physiology that includes decreased functional residual capacity. (See",
"    <a class=\"local\" href=\"#H20091528\">",
"     'Obesity-related physiologic changes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    General anesthesia further decreases functional residual capacity, and gas exchange is altered more profoundly in morbidly obese patients than in nonobese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/101\">",
"     101",
"    </a>",
"    ]. Moreover, these changes persist longer during the postoperative period, rendering obese patients vulnerable to postoperative respiratory complications.",
"   </p>",
"   <p>",
"    For intubated patients undergoing general anesthesia, oxygenation can be improved by vital capacity or recruitment maneuvers, which consists of the application of a positive inspiratory pressure between 35 and 55 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O for a brief period, possibly followed by positive end-expiratory pressure of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/7,8,102-104\">",
"     7,8,102-104",
"    </a>",
"    ]. Recruitment maneuvers should not be performed until after hemodynamic stabilization following induction of general anesthesia has been achieved, and the patient is euvolemic. During laparoscopic surgery in morbidly obese patients, a positive end-expiratory pressure (PEEP) of approximately 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O is effective in maintaining functional residual capacity and improving oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. However, higher levels of PEEP can induce hypotension due to decreased venous return, and patients may require increased fluid administration or vasopressors to maintain their blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/103,105,107\">",
"     103,105,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link\">",
"     \"Postoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the completion of the procedure, the endotracheal tube should be removed in the operating room only if the patient is fully awake, reversed from neuromuscular blockade, and meets standard extubation criteria. Some patients may be slow to emerge from anesthesia, and will need to remain intubated for a short period of time in the recovery room. The severely obese patient who requires early re-intubation following surgery may have swelling and edema due to the prior surgical intervention and airway manipulation. These changes can pose unexpected challenges for repeat airway management and should be anticipated. Availability of adequate airway equipment and personnel to assist in airway management should be arranged, up to and including the potential need for a surgical airway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=see_link\">",
"     \"Devices for difficult emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of 209 normal-weight patients at risk for respiratory failure found that early treatment of postoperative hypoxemia with noninvasive positive pressure ventilation (NIPPV) significantly reduced the incidence of reintubation, ICU length of stay, pneumonia, infection and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/108\">",
"     108",
"    </a>",
"    ]. In morbidly obese patients with obstructive sleep apnea undergoing laparoscopic bariatric surgery, NIPPV given immediately after extubation was found to significantly improve lung spirometry values at one hour and one day postoperatively, compared with continuous positive airway pressure (CPAP) started in the PACU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/109\">",
"     109",
"    </a>",
"    ]. The use of NIPPV is feasible in previously untrained patients in the presence of a trained respiratory technician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediate postoperative use of continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) treatment of obese patients, particularly following intestinal surgery, should no longer be regarded as controversial. Based on data in nonobese and obese patients, CPAP can be recommended for the treatment of hypoxemia in the immediate postoperative period for most obese patients. Following gastrointestinal surgery such as gastric bypass, we prefer early joint decision between anesthesiologist, surgeon, respiratory technician and nurse to determine CPAP use in selected patients, emphasizing the team concept for the perioperative care of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12\">",
"     12",
"    </a>",
"    ]. Institutions are encouraged to develop protocols and pathways for perioperative care of obese patients that include standardized procedures for the use of CPAP or BiPAP.",
"   </p>",
"   <p>",
"    Aspiration of air during CPAP treatment with possible disruption of fresh anastomotic suture lines was thought to be a concern and supported by at least one case report following gastric bypass surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/111\">",
"     111",
"    </a>",
"    ]. However, in a prospective study of 1067 gastric bypass patients, 15 anastomotic leaks occurred but only two were in patients using CPAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/112\">",
"     112",
"    </a>",
"    ]. The authors concluded that CPAP is useful for treating hypoventilation without significantly increasing the risk for anastomotic leak. In another study in 310 patients undergoing gastric bypass surgery, 91 patients were treated postoperatively with CPAP and no anastomotic leaks occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians would still prefer to avoid immediate postoperative positive airway pressure therapy. In a prospective study of 1095 patients who underwent laparoscopic gastric bypass surgery, 811 patients had no known history of OSA and 284 patients had confirmed OSA. Of these 284 patients, 144 were considered CPAP or BiPAP dependant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/114\">",
"     114",
"    </a>",
"    ]. Postoperative positive airway pressure therapy was withheld in all cases, but aggressive incentive spirometry and early ambulation were instituted. No significant differences were found in length of stay or pulmonary complications between groups. No anastomotic leaks or deaths occurred in any of the patients and the authors concluded that postoperative positive pressure therapy can be safely omitted following laparoscopic gastric bypass surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245896\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal fluid management remains an unresolved issue in the general surgical population, let alone the population of obese surgical patients. Little to no generalizable evidence exists, other than accepted practice standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12,115\">",
"     12,115",
"    </a>",
"    ]. Intraoperative and perioperative fluid strategies in severely obese patients aim to maintain euvolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12\">",
"     12",
"    </a>",
"    ]. However, euvolemia in this population is poorly defined, and clinical judgment based upon available measures of volume status and tissue perfusion remains the most important factor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=see_link\">",
"     \"Intraoperative fluid management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702538\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;No high-quality evidence is available to suggest that intraoperative monitoring in the obese patient should be any different compared with normal-weight individuals. The intensity of intraoperative patient monitoring should be guided by the type of surgery and the patient&rsquo;s comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the majority of patients, we use standard intraoperative monitoring, including oxygenation, ventilation, blood pressure, heart rate and body temperature. An appropriately-sized and possibly conically-shaped blood pressure cuff for noninvasive blood pressure (NIBP) measurement is desirable. However, alternative cuff location (eg, forearm or lower leg) is acceptable for most situations when body habitus prevents correct cuff positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12\">",
"     12",
"    </a>",
"    ]. No studies are available that have determined the accuracy of alternative NIBP cuff locations and possible size mismatches. However, widespread use of NIBP assessment rather than routine invasive monitoring has shown this clinical practice to be safe for the majority of obese patients. If noninvasive blood pressure monitoring is technically not feasible, the threshold for arterial catheter placement should be low. As with the placement of peripheral nerve blocks or neuraxial anesthetics, ultrasound guidance may also be useful for arterial catheter placement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain monitoring devices using a processed EEG to assess depth of anesthesia can provide useful information during anesthetic delivery and recovery in morbidly obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/86,87,116,117\">",
"     86,87,116,117",
"    </a>",
"    ]. These devices allow anesthetic agents to be titrated to achieve and maintain a desired level of anesthesia. Brain monitoring devices and monitoring for anesthetic underdosing are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link\">",
"     \"Awareness with recall following general anesthesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The obese patient requiring emergency surgery or returning emergently to the operating room within 24 to 48 hours of the initial major surgery can be a unique challenge to the care team. The patient&rsquo;s physical status is often altered and the patient may exhibit signs of an early systemic inflammatory response following major surgery. There is essentially no literature to guide the caregivers in this situation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link&amp;anchor=H5#H5\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Systemic inflammatory response syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anesthesia and surgical teams should have a low threshold to establish additional vascular access and implement invasive arterial blood pressure monitoring, preferably prior to the induction of general anesthesia. Central venous access may be helpful for drug and fluid administration as well as assessment of the patient&rsquo;s fluid status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708418\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The improperly positioned obese surgical patient can experience serious physiologic impairment, and even physical injury. Certain surgical positions are more hazardous than others in altering baseline cardiovascular and pulmonary function. (See",
"    <a class=\"local\" href=\"#H20091528\">",
"     'Obesity-related physiologic changes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is little evidence in the literature evaluating specific measures particular to positioning of morbidly obese patients during surgery or in the recovery room. Therefore, a common-sense approach should be taken that includes positioning the patient on an appropriately-sized operating room table, recovery stretcher or bed, and carefully padding pressure points especially between exposed limbs and guard-rails. Intraoperative positioning focuses on prevention of peripheral nerve injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    A comprehensive review of different intraoperative surgical positions and their impact on cardio-pulmonary function in obese patients is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/118\">",
"     118",
"    </a>",
"    ], but there are no studies that address specific strategies that conclusively prevent or ameliorate potential detrimental effects beyond what is known for the surgical population in general. However, the Trendelenburg, lithotomy and particularly the prone position should be avoided in the morbidly obese patient whenever possible, because these exacerbate restrictive pulmonary physiology. In selected morbidly obese patients requiring prone positioning for surgery, we have successfully practiced awake fiberoptic intubation and self-prone positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/119\">",
"     119",
"    </a>",
"    ]. This strategy avoids the need for extended personnel for assistance with positioning and allows the patient to assume a comfortable position prior to induction of general anesthesia. During lateral positioning, care must be taken to avoid compression of the groin region as lower extremity ischemia has been reported in the dependent extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperatively, strictly supine positioning should be avoided in obese patients. A 30�� upper body and head elevated position should be chosen. This position reduces the negative effects associated with a horizontal supine position including hypoxemia due to the restrictive pulmonary physiology, decreased functional residual capacity and airway obstruction.",
"   </p>",
"   <p>",
"    The semi-upright position and avoiding the supine position whenever possible are also recommended by the American Society of Anesthesiologists for postoperative recovery in patients with obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"     27",
"    </a>",
"    ]. In one study of patients with obstructive sleep apnea, the lateral decubitus position maintained airway patency by increasing the diameter of the pharyngeal airway compared with supine positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/121\">",
"     121",
"    </a>",
"    ]. The lateral decubitus position combined with head and upper body elevation should be used during recovery from general anesthesia unless contraindicated due to the nature of the surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19621685\">",
"    <span class=\"h2\">",
"     Discharge criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is very little objective evidence in the literature to guide clinical decision-making regarding duration of postoperative monitoring in morbidly obese patients. Standards for the postoperative care of surgical patients published by the American Society of Anesthesiologists (ASA) should be followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/122\">",
"     122",
"    </a>",
"    ]. However, the ASA recently published practice guidelines for the perioperative care of patients with obstructive sleep apnea (OSA), mostly based on expert opinion consensus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"     27",
"    </a>",
"    ]. These guidelines suggest that prior to transfer of the patient to an unmonitored setting, their oxygen saturation on room air should return to their baseline, and when left undisturbed the patient should not develop clinical hypoxemia or airway obstruction.",
"   </p>",
"   <p>",
"    It has been suggested that patients with OSA may need to be continuously monitored with pulse oximetry for a median of three hours longer than their non-OSA counterparts, and that monitoring should continue for a median of seven hours after the last episode of hypoxemia or airway obstruction. There are no studies examining whether this monitoring reduces risk or improves outcomes in OSA patients. In our practice, we adhere to the ASA standards with a low threshold for prolonged recovery room monitoring based upon the individual patient&rsquo;s course.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086370479\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percentage of severely obese and morbidly obese patients in the population is increasing and it is relatively common for the anesthesiologist to administer anesthesia to patients who meet criteria for morbid obesity (ie, body mass index [BMI] &gt;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for routine elective surgery or surgery for weight loss. (See",
"      <a class=\"local\" href=\"#H1086370192\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe obesity is associated with physiologic changes that impact the delivery of anesthesia. These include alterations in oropharyngeal anatomy, pulmonary mechanics and the pharmacokinetics of drug absorption and elimination. (See",
"      <a class=\"local\" href=\"#H20091528\">",
"       'Obesity-related physiologic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation of severely obese patients undergoing major surgery should include consultation with an anesthesiologist. Although increased body mass index in the absence of comorbidities is not associated with adverse postoperative outcomes in patients undergoing noncardiac surgery (except for thromboembolism), the presence of metabolic syndrome, cardiovascular disease, hypertension, type 2 diabetes mellitus, obstructive sleep apnea, and kidney disease increase the risk for complications. (See",
"      <a class=\"local\" href=\"#H1086370207\">",
"       'Anesthesia consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anesthesiology consultation, including history and physical examination and selective preoperative testing, aims to identify those severely obese patients who have silent comorbidities and those at risk for airway and respiratory compromise during and following anesthesia. (See",
"      <a class=\"local\" href=\"#H1065684\">",
"       'Preoperative testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative nocturnal positive pressure airway therapy is beneficial in severely obese patients with established or newly diagnosed obstructive sleep apnea. Preoperative positive airway pressure therapy is associated with improvements in physiology that facilitate anesthetic management. (See",
"      <a class=\"local\" href=\"#H708499\">",
"       'Positive airway pressure therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link&amp;anchor=H15227539#H15227539\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\", section on 'Preoperative evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of anesthetic technique for severely obese patients should be guided by the requirements of the surgical procedure, comorbidities and patient preferences. General anesthesia, regional anesthetic and sedation techniques have all been employed safely in obese patients, and no technique has been found to be superior over another with respect to important clinical outcomes. Regardless of technique chosen, the goals for anesthetic management of obese patients (and particularly in the presence of sleep apnea) include minimizing opioid administration to decrease the risk of respiratory depression, and when using general anesthesia, to allow rapid emergence. (See",
"      <a class=\"local\" href=\"#H708223\">",
"       'Anesthetic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prone, flat supine and Trendelenburg positioning should be avoided in severely obese patients whenever possible. Postoperatively, a head up 30&deg; position combined with a lateral decubitus positioning, when possible, minimizes compromise to airway and respiratory function. (See",
"      <a class=\"local\" href=\"#H708418\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In severely obese patients, we suggest using multimodal analgesia that is opioid-sparing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Multimodal analgesia including the use of non-steroidal anti-inflammatory drugs, alpha-2 agonists and wound infiltration with local anesthetic reduces the risk for respiratory depression and other opioid-related side effects. (See",
"      <a class=\"local\" href=\"#H19621384\">",
"       'Multimodal analgesia'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Postoperatively, strategies to reduce pulmonary complications in severely obese patients include early institution of noninvasive positive pressure ventilation (NIPPV) for hypoxemia, early ambulation, and other measures to decrease postoperative atelectasis (eg, head-up positioning, positive airway pressure therapy, incentive spirometry). (See",
"      <a class=\"local\" href=\"#H19621674\">",
"       'Respiratory care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body mass index &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      does not appear by itself to be a contraindication to outpatient surgery in severely obese patients. However, there are no high-quality studies to guide patient or procedure selection. Factors important to safely perform surgical procedures at freestanding ambulatory facilities include the immediate availability of emergency difficult airway equipment, advanced respiratory care equipment, access to laboratory and radiology facilities, and transfer agreements for patient transfer to an external facility. The establishment of clinical pathways for the care of obese patients undergoing a variety of procedures, and particularly for those procedures performed in the day surgery setting, may reduce morbidity. (See",
"      <a class=\"local\" href=\"#H708522\">",
"       'Ambulatory versus inpatient surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/1\">",
"      Levin PD, Weissman C. Obesity, metabolic syndrome, and the surgical patient. Med Clin North Am 2009; 93:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Bariatric Surgical Society takes on new name, new mission and new surgery: Metabolic surgery expected to play bigger role in treating type 2 diabetes and other metabolic diseases. www.asbs.org/Newsite07/resources/press_release_8202007.pdf (Accessed on December 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/3\">",
"      Williamson JA, Webb RK, Szekely S, et al. The Australian Incident Monitoring Study. Difficult intubation: an analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/4\">",
"      Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. Anesth Analg 2002; 94:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/5\">",
"      Gonzalez H, Minville V, Delanoue K, et al. The importance of increased neck circumference to intubation difficulties in obese patients. Anesth Analg 2008; 106:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/6\">",
"      Isono S. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. Anesthesiology 2009; 110:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/7\">",
"      Pelosi P, Gregoretti C. Perioperative management of obese patients. Best Pract Res Clin Anaesthesiol 2010; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/8\">",
"      Ladosky W, Botelho MA, Albuquerque JP Jr. Chest mechanics in morbidly obese non-hypoventilated patients. Respir Med 2001; 95:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/9\">",
"      Kabon B, Nagele A, Reddy D, et al. Obesity decreases perioperative tissue oxygenation. Anesthesiology 2004; 100:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/10\">",
"      Passannante AN, Rock P. Anesthetic management of patients with obesity and sleep apnea. Anesthesiol Clin North America 2005; 23:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/11\">",
"      Schumann R, Jones SB, Ortiz VE, et al. Best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery. Obes Res 2005; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/12\">",
"      Schumann R, Jones SB, Cooper B, et al. Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007. Obesity (Silver Spring) 2009; 17:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/13\">",
"      Lee A, Lum ME, Hillman KM, Bauman A. Referral of surgical patients to an anaesthetic clinic: a decision-making analysis. Anaesth Intensive Care 1994; 22:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/14\">",
"      van Klei WA, Moons KG, Rutten CL, et al. The effect of outpatient preoperative evaluation of hospital inpatients on cancellation of surgery and length of hospital stay. Anesth Analg 2002; 94:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/15\">",
"      Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. Lancet 2003; 361:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/16\">",
"      Mullen JT, Moorman DW, Davenport DL. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg 2009; 250:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/17\">",
"      Akinnusi ME, Pineda LA, El Solh AA. Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med 2008; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/18\">",
"      Glance LG, Wissler R, Mukamel DB, et al. Perioperative outcomes among patients with the modified metabolic syndrome who are undergoing noncardiac surgery. Anesthesiology 2010; 113:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/19\">",
"      Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/20\">",
"      Mickelson SA. Preoperative and postoperative management of obstructive sleep apnea patients. Otolaryngol Clin North Am 2007; 40:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/21\">",
"      Kuruba R, Koche LS, Murr MM. Preoperative assessment and perioperative care of patients undergoing bariatric surgery. Med Clin North Am 2007; 91:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/22\">",
"      American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Practice advisory for preanesthesia evaluation: a report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology 2002; 96:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/23\">",
"      Ramaswamy A, Gonzalez R, Smith CD. Extensive preoperative testing is not necessary in morbidly obese patients undergoing gastric bypass. J Gastrointest Surg 2004; 8:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/24\">",
"      Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009; 120:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/25\">",
"      Smetana GW, Lawrence VA, Cornell JE, American College of Physicians. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/26\">",
"      O'Keeffe T, Patterson EJ. Evidence supporting routine polysomnography before bariatric surgery. Obes Surg 2004; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/27\">",
"      Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/28\">",
"      Sinha AC. Some anesthetic aspects of morbid obesity. Curr Opin Anaesthesiol 2009; 22:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/29\">",
"      Abrishami A, Khajehdehi A, Chung F. A systematic review of screening questionnaires for obstructive sleep apnea. Can J Anaesth 2010; 57:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/30\">",
"      Ramachandran SK, Kheterpal S, Consens F, et al. Derivation and validation of a simple perioperative sleep apnea prediction score. Anesth Analg 2010; 110:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/31\">",
"      Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/32\">",
"      Gupta RM, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin Proc 2001; 76:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/33\">",
"      Ryan CF, Lowe AA, Li D, Fleetham JA. Magnetic resonance imaging of the upper airway in obstructive sleep apnea before and after chronic nasal continuous positive airway pressure therapy. Am Rev Respir Dis 1991; 144:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/34\">",
"      Golbin JM, Somers VK, Caples SM. Obstructive sleep apnea, cardiovascular disease, and pulmonary hypertension. Proc Am Thorac Soc 2008; 5:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/35\">",
"      Cartagena R. Preoperative evaluation of patients with obesity and obstructive sleep apnea. Anesthesiol Clin North America 2005; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/36\">",
"      Dorkova Z, Petrasova D, Molcanyiova A, et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/37\">",
"      Warner DO. Perioperative abstinence from cigarettes: physiologic and clinical consequences. Anesthesiology 2006; 104:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/38\">",
"      Warner DO, American Society of Anesthesiologists Smoking Cessation Initiative Task Force. Feasibility of tobacco interventions in anesthesiology practices: a pilot study. Anesthesiology 2009; 110:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/39\">",
"      Atkins M, White J, Ahmed K. Day surgery and body mass index: results of a national survey. Anaesthesia 2002; 57:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/40\">",
"      Ni KM, Watts JC. Obesity and day-case surgery in an isolated unit. Anaesthesia 2002; 57:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/41\">",
"      Shnaider I, Chung F. Outcomes in day surgery. Curr Opin Anaesthesiol 2006; 19:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/42\">",
"      Candiotti K, Sharma S, Shankar R. Obesity, obstructive sleep apnoea, and diabetes mellitus: anaesthetic implications. Br J Anaesth 2009; 103 Suppl 1:i23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/43\">",
"      Lermitte J, Chung F. Patient selection in ambulatory surgery. Curr Opin Anaesthesiol 2005; 18:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/44\">",
"      Montgomery KF, Watkins BM, Ahroni JH, et al. Outpatient laparoscopic adjustable gastric banding in super-obese patients. Obes Surg 2007; 17:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/45\">",
"      Yeats M, Wedergren S, Fox N, Thompson JS. The use and modification of clinical pathways to achieve specific outcomes in bariatric surgery. Am Surg 2005; 71:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/46\">",
"      M&uuml;ller MK, Dedes KJ, Dindo D, et al. Impact of clinical pathways in surgery. Langenbecks Arch Surg 2009; 394:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/47\">",
"      Campillo-Soto A, Mart&iacute;n-Lorenzo JG, Lir&oacute;n-Ru&iacute;z R, et al. Evaluation of the clinical pathway for laparoscopic bariatric surgery. Obes Surg 2008; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/48\">",
"      Chung SA, Yuan H, Chung F. A systemic review of obstructive sleep apnea and its implications for anesthesiologists. Anesth Analg 2008; 107:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/49\">",
"      Prielipp RC. An anesthesiologist's perspective on inhaled anesthesia decision-making. Am J Health Syst Pharm 2010; 67:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/50\">",
"      Lohser J, Kulkarni V, Brodsky JB. Anesthesia for thoracic surgery in morbidly obese patients. Curr Opin Anaesthesiol 2007; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/51\">",
"      Strum EM, Szenohradszki J, Kaufman WA, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. Anesth Analg 2004; 99:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/52\">",
"      De Baerdemaeker LE, Jacobs S, Den Blauwen NM, et al. Postoperative results after desflurane or sevoflurane combined with remifentanil in morbidly obese patients. Obes Surg 2006; 16:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/53\">",
"      Arain SR, Barth CD, Shankar H, Ebert TJ. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. J Clin Anesth 2005; 17:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/54\">",
"      Vallejo MC, Sah N, Phelps AL, et al. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. J Clin Anesth 2007; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/55\">",
"      Leykin Y, Pellis T, Del Mestro E, et al. Anesthetic management of morbidly obese and super-morbidly obese patients undergoing bariatric operations: hospital course and outcomes. Obes Surg 2006; 16:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/56\">",
"      Brodsky JB, Lemmens HJ, Collins JS, et al. Nitrous oxide and laparoscopic bariatric surgery. Obes Surg 2005; 15:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/57\">",
"      Ingrande J, Brodsky JB, Lemmens HJ. Regional anesthesia and obesity. Curr Opin Anaesthesiol 2009; 22:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/58\">",
"      Ellinas EH, Eastwood DC, Patel SN, et al. The effect of obesity on neuraxial technique difficulty in pregnant patients: a prospective, observational study. Anesth Analg 2009; 109:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/59\">",
"      von Ungern-Sternberg BS, Regli A, Bucher E, et al. Impact of spinal anaesthesia and obesity on maternal respiratory function during elective Caesarean section. Anaesthesia 2004; 59:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/60\">",
"      Whitty RJ, Maxwell CV, Carvalho JC. Complications of neuraxial anesthesia in an extreme morbidly obese patient for Cesarean section. Int J Obstet Anesth 2007; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/61\">",
"      Bamgbade OA, Khalaf WM, Ajai O, et al. Obstetric anaesthesia outcome in obese and non-obese parturients undergoing caesarean delivery: an observational study. Int J Obstet Anesth 2009; 18:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/62\">",
"      Ahmad S, Nagle A, McCarthy RJ, et al. Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg 2008; 107:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/63\">",
"      von Ungern-Sternberg BS, Regli A, Reber A, Schneider MC. Effect of obesity and thoracic epidural analgesia on perioperative spirometry. Br J Anaesth 2005; 94:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/64\">",
"      Rigg JR, Jamrozik K, Myles PS, et al. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet 2002; 359:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/65\">",
"      Sharma M, Mehta Y, Sawhney R, et al. Thoracic epidural analgesia in obese patients with body mass index of more than 30 kg/m2 for off pump coronary artery bypass surgery. Ann Card Anaesth 2010; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/66\">",
"      Nielsen KC, Guller U, Steele SM, et al. Influence of obesity on surgical regional anesthesia in the ambulatory setting: an analysis of 9,038 blocks. Anesthesiology 2005; 102:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/67\">",
"      Schwemmer U, Papenfuss T, Greim C, et al. Ultrasound-guided interscalene brachial plexus anaesthesia: differences in success between patients of normal and excessive weight. Ultraschall Med 2006; 27:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/68\">",
"      Franco CD, Gloss FJ, Voronov G, et al. Supraclavicular block in the obese population: an analysis of 2020 blocks. Anesth Analg 2006; 102:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/69\">",
"      Hanouz JL, Grandin W, Lesage A, et al. Multiple injection axillary brachial plexus block: influence of obesity on failure rate and incidence of acute complications. Anesth Analg 2010; 111:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/70\">",
"      Alvarez AO, Cascardo A, Albarracin Menendez S, et al. Total intravenous anesthesia with midazolam, remifentanil, propofol and cistracurium in morbid obesity. Obes Surg 2000; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/71\">",
"      Madan AK, Tichansky DS, Isom J, et al. Monitored anesthesia care with propofol versus surgeon-monitored sedation with benzodiazepines and narcotics for preoperative endoscopy in the morbidly obese. Obes Surg 2008; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/72\">",
"      Lemmens HJ. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010; 23:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/73\">",
"      Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/74\">",
"      Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight (\"pharmacokinetic mass\"). Anesthesiology 2004; 101:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/75\">",
"      Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth 2005; 95:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/76\">",
"      Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/77\">",
"      Slepchenko G, Simon N, Goubaux B, et al. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology 2003; 98:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/78\">",
"      Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/79\">",
"      Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/80\">",
"      Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/81\">",
"      Barrio J, San Miguel G, Molina I, et al. [Clinical effect of mivacurium in morbidly obese patients]. Rev Esp Anestesiol Reanim 2006; 53:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/82\">",
"      Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/83\">",
"      Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/84\">",
"      Tejirian T, Lewis CE, Conner J, et al. Succinylcholine: a drug to avoid in bariatric surgery. Obes Surg 2009; 19:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/85\">",
"      Pawlik MT, Hansen E, Waldhauser D, et al. Clonidine premedication in patients with sleep apnea syndrome: a randomized, double-blind, placebo-controlled study. Anesth Analg 2005; 101:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/86\">",
"      Feld JM, Hoffman WE, Stechert MM, et al. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth 2006; 18:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/87\">",
"      Tufanogullari B, White PF, Peixoto MP, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg 2008; 106:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/88\">",
"      Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, et al. Effects of dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. Middle East J Anesthesiol 2007; 19:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/89\">",
"      Hofer RE, Sprung J, Sarr MG, Wedel DJ. Anesthesia for a patient with morbid obesity using dexmedetomidine without narcotics. Can J Anaesth 2005; 52:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/90\">",
"      Ebert TJ, Shankar H, Haake RM. Perioperative considerations for patients with morbid obesity. Anesthesiol Clin 2006; 24:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/91\">",
"      Govindarajan R, Ghosh B, Sathyamoorthy MK, et al. Efficacy of ketorolac in lieu of narcotics in the operative management of laparoscopic surgery for morbid obesity. Surg Obes Relat Dis 2005; 1:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/92\">",
"      Feld JM, Laurito CE, Beckerman M, et al. Non-opioid analgesia improves pain relief and decreases sedation after gastric bypass surgery. Can J Anaesth 2003; 50:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/93\">",
"      Sollazzi L, Modesti C, Vitale F, et al. Preinductive use of clonidine and ketamine improves recovery and reduces postoperative pain after bariatric surgery. Surg Obes Relat Dis 2009; 5:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/94\">",
"      Kamelgard JI, Kim KA, Atlas G. Combined preemptive and preventive analgesia in morbidly obese patients undergoing open gastric bypass: A pilot study. Surg Obes Relat Dis 2005; 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/95\">",
"      Schumann R, Shikora S, Weiss JM, et al. A comparison of multimodal perioperative analgesia to epidural pain management after gastric bypass surgery. Anesth Analg 2003; 96:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/96\">",
"      Meissner W. The role of acupuncture and transcutaneous-electrical nerve stimulation for postoperative pain control. Curr Opin Anaesthesiol 2009; 22:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/97\">",
"      Neligan PJ, Porter S, Max B, et al. Obstructive sleep apnea is not a risk factor for difficult intubation in morbidly obese patients. Anesth Analg 2009; 109:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/98\">",
"      Chung F, Mezei G, Tong D. Pre-existing medical conditions as predictors of adverse events in day-case surgery. Br J Anaesth 1999; 83:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/99\">",
"      Bell RL, Rosenbaum SH. Postoperative considerations for patients with obesity and sleep apnea. Anesthesiol Clin North America 2005; 23:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/100\">",
"      Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II patients. Dig Dis Sci 2009; 54:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/101\">",
"      Hans GA, Lauwick S, Kaba A, et al. Postoperative respiratory problems in morbidly obese patients. Acta Anaesthesiol Belg 2009; 60:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/102\">",
"      Chalhoub V, Yazigi A, Sleilaty G, et al. Effect of vital capacity manoeuvres on arterial oxygenation in morbidly obese patients undergoing open bariatric surgery. Eur J Anaesthesiol 2007; 24:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/103\">",
"      Whalen FX, Gajic O, Thompson GB, et al. The effects of the alveolar recruitment maneuver and positive end-expiratory pressure on arterial oxygenation during laparoscopic bariatric surgery. Anesth Analg 2006; 102:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/104\">",
"      Reinius H, Jonsson L, Gustafsson S, et al. Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis: a computerized tomography study. Anesthesiology 2009; 111:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/105\">",
"      Erlandsson K, Odenstedt H, Lundin S, Stenqvist O. Positive end-expiratory pressure optimization using electric impedance tomography in morbidly obese patients during laparoscopic gastric bypass surgery. Acta Anaesthesiol Scand 2006; 50:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/106\">",
"      Talab HF, Zabani IA, Abdelrahman HS, et al. Intraoperative ventilatory strategies for prevention of pulmonary atelectasis in obese patients undergoing laparoscopic bariatric surgery. Anesth Analg 2009; 109:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/107\">",
"      Bohm SH, Thamm OC, von Sandersleben A, et al. Alveolar recruitment strategy and high positive end-expiratory pressure levels do not affect hemodynamics in morbidly obese intravascular volume-loaded patients. Anesth Analg 2009; 109:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/108\">",
"      Squadrone V, Coha M, Cerutti E, et al. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA 2005; 293:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/109\">",
"      Neligan PJ, Malhotra G, Fraser M, et al. Noninvasive ventilation immediately after extubation improves lung function in morbidly obese patients with obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg 2010; 110:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/110\">",
"      Battisti A, Michotte JB, Tassaux D, et al. Non-invasive ventilation in the recovery room for postoperative respiratory failure: a feasibility study. Swiss Med Wkly 2005; 135:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/111\">",
"      Vasquez TL, Hoddinott K. A potential complication of bi-level positive airway pressure after gastric bypass surgery. Obes Surg 2004; 14:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/112\">",
"      Huerta S, DeShields S, Shpiner R, et al. Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. J Gastrointest Surg 2002; 6:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/113\">",
"      Ramirez A, Lalor PF, Szomstein S, Rosenthal RJ. Continuous positive airway pressure in immediate postoperative period after laparoscopic Roux-en-Y gastric bypass: is it safe? Surg Obes Relat Dis 2009; 5:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/114\">",
"      Jensen C, Tejirian T, Lewis C, et al. Postoperative CPAP and BiPAP use can be safely omitted after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2008; 4:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/115\">",
"      Wool DB, Lemmens HJ, Brodsky JB, et al. Intraoperative fluid replacement and postoperative creatine phosphokinase levels in laparoscopic bariatric patients. Obes Surg 2010; 20:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/116\">",
"      Pandazi A, Bourlioti A, Kostopanagiotou G. Bispectral Index (BIS) monitoring in morbidly obese patients undergoing gastric bypass surgery: experience in 23 patients. Obes Surg 2005; 15:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/117\">",
"      Meyhoff CS, Henneberg SW, J&oslash;rgensen BG, et al. Depth of anaesthesia monitoring in obese patients: a randomized study of propofol-remifentanil. Acta Anaesthesiol Scand 2009; 53:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/118\">",
"      Brodsky JB. Positioning the morbidly obese patient for anesthesia. Obes Surg 2002; 12:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/119\">",
"      Wu SD, Yilmaz M, Tamul PC, et al. Awake endotracheal intubation and prone patient self-positioning: anesthetic and positioning considerations during percutaneous nephrolithotomy in obese patients. J Endourol 2009; 23:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/120\">",
"      Newton G, White E. Femoral artery occlusion in obese patients in the lateral position. Anaesthesia 2010; 65:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/41/35482/abstract/121\">",
"      Isono S, Tanaka A, Nishino T. Lateral position decreases collapsibility of the passive pharynx in patients with obstructive sleep apnea. Anesthesiology 2002; 97:780.",
"     </a>",
"    </li>",
"    <li>",
"     www.asahq.org (Accessed on December 08, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14932 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-131D73BB27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35482=[""].join("\n");
var outline_f34_41_35482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1086370479\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370192\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20091528\">",
"      OBESITY-RELATED PHYSIOLOGIC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370207\">",
"      ANESTHESIA CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370214\">",
"      Evaluation of comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1065684\">",
"      Preoperative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704994\">",
"      Preoperative counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H708499\">",
"      - Positive airway pressure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370238\">",
"      - Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H708522\">",
"      - Ambulatory versus inpatient surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H708223\">",
"      ANESTHETIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370269\">",
"      Inhalational agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705003\">",
"      Neuraxial anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702495\">",
"      Peripheral nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705010\">",
"      Intravenous anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19621584\">",
"      ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19621384\">",
"      Multimodal analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19621431\">",
"      Alternative analgesic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H702530\">",
"      PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705031\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19621674\">",
"      Respiratory care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H245896\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702538\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H708418\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19621685\">",
"      Discharge criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1086370479\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14932|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/50/21285\" title=\"picture 1\">",
"      RAMP position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/27/17852\" title=\"table 1\">",
"      Ideal body weight lean body weight approximation table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/61/11227\" title=\"table 2A\">",
"      Severity of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/41/22173\" title=\"table 2B\">",
"      OSA scoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/11/31932\" title=\"table 3A\">",
"      OSA symptoms questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/20/42316\" title=\"table 3B\">",
"      Identify and assess OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/46/19181\" title=\"table 4\">",
"      Weight-based dosing of anesthetic medications in severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/21/29009?source=related_link\" title=\"calculator 1\">",
"      Calculator: Lean body weight (adult male)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/26/29089?source=related_link\" title=\"calculator 2\">",
"      Calculator: Lean body weight (adult female)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=related_link\" title=\"calculator 3\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=related_link\" title=\"calculator 4\">",
"      Calculator: Body mass index for adults (Patient information)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20329?source=related_link\">",
"      Emergency airway management in the morbidly obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=related_link\">",
"      Intraoperative fluid management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=related_link\">",
"      Intraoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=related_link\">",
"      Postoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28966?source=related_link\">",
"      Screening for chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_41_35483="Functional classificat HF";
var content_f34_41_35483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Functional classification of patients with heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        VO",
"        <sub>",
"         2",
"        </sub>",
"        max, mL/kg/min",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anaerobic threshold, mL/kg/min",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximal cardiac index, L/min/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        None to mild",
"       </td>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        &gt;14",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"       <td>",
"        16-20",
"       </td>",
"       <td>",
"        11-14",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Moderate to severe",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        8-11",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        6-9",
"       </td>",
"       <td>",
"        5-8",
"       </td>",
"       <td>",
"        2-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        Very severe",
"       </td>",
"       <td>",
"        &lt;6",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Weber KT, Janicki JS. CardioPulmonary Exercise Testing. Physiologic Principles and Clinical Applications. WB Saunders, Philadelphia, 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35483=[""].join("\n");
var outline_f34_41_35483=null;
var title_f34_41_35484="Classification and management of blood pressure";
var content_f34_41_35484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and management of blood pressure for adults aged 18 years or older",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        BP classification",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Systolic BP mmHg*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Diastolic BP mmHg*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Management*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"1\" rowspan=\"2\">",
"        Lifestyle modification",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Initial drug therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Without compelling indication",
"       </td>",
"       <td class=\"subtitle3\">",
"        With compelling indications&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        and",
"       </td>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        Encourage",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prehypertension",
"       </td>",
"       <td>",
"        120-139",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        80-89",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No antihypertensive drug indicated",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 1 hypertension",
"       </td>",
"       <td>",
"        140-159",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        90-99",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Thiazide-type diuretics for most; may consider ACE inhibitor, ARB, beta blocker, CCB, or combination",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications; other anti-hypertensive drugs (diuretics, ACE inhibitor, ARB, beta blocker, CCB) as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 2 hypertension",
"       </td>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        &ge;100",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2-drug combination for most (usually thiazide-type diuretic and ACE inhibitor or ARB or beta blocker or CCB)&loz;",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications; other antihypertensive drugs (diuretics, ACE inhibitor, ARB, beta blocker, CCB) as needed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; BP: blood pressure; CCB: calcium channel blocker.",
"     <br>",
"      * Treatment determined by highest BP category.",
"      <br>",
"       &Delta; Treat patients with chronic kidney disease or diabetes to BP goal of less than 130/80 mmHg. Other compelling indications include disorders such as heart failure, post-myocardial infarction, and atrial fibrillation in which particular antihypertensive drugs are warranted independent of BP.",
"       <br>",
"        &loz; Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35484=[""].join("\n");
var outline_f34_41_35484=null;
var title_f34_41_35485="Biochem clin feat MPS A";
var content_f34_41_35485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biochemical and clinical features of the mucopolysaccharidoses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzyme deficient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Substrate accumulated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual age at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key distinct findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Skeletal disease, soft tissue storage, and a range of CNS disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        MPS I",
"       </td>",
"       <td>",
"        Hurler",
"       </td>",
"       <td rowspan=\"3\">",
"        &alpha;-L-iduronidase",
"       </td>",
"       <td rowspan=\"3\">",
"        Heparan sulfate Dermatan sulfate",
"       </td>",
"       <td>",
"        1-2 y",
"       </td>",
"       <td>",
"        Developmental delay, severe coarse facies, hepatosplenomegaly, airway obstruction, dystosis multiplex, often placid and loving, death by age 10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hurler-Scheie",
"       </td>",
"       <td>",
"        1-5 y",
"       </td>",
"       <td>",
"        Micrognathia, toe walking, moderate coarse facies, possible normal intelligence, death by 20s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scheie",
"       </td>",
"       <td>",
"        3-15 y",
"       </td>",
"       <td>",
"        Aortic valve, joint dz, corneal clouding, normal facies, death in decades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        MPS II",
"       </td>",
"       <td>",
"        Hunter severe",
"       </td>",
"       <td rowspan=\"2\">",
"        Iduronate sulfatase",
"       </td>",
"       <td rowspan=\"2\">",
"        Heparan sulfate Dermatan sulfate",
"       </td>",
"       <td>",
"        1-3 y",
"       </td>",
"       <td>",
"        No corneal clouding, physical disease similar to MPS I, aggressive behavior and developmental delay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hunter mild",
"       </td>",
"       <td>",
"        1-5 y",
"       </td>",
"       <td>",
"        Normal or near-normal intelligence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        MPS VII",
"       </td>",
"       <td>",
"        Sly",
"       </td>",
"       <td rowspan=\"3\">",
"        &beta;-glucoronidase",
"       </td>",
"       <td rowspan=\"3\">",
"        Heparan sulfate Dermatan sulfate",
"       </td>",
"       <td>",
"        Birth-5 y",
"       </td>",
"       <td>",
"        Variable intermediate presentation similar to MPS I, death in teens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal hydrops",
"       </td>",
"       <td>",
"        In utero to birth",
"       </td>",
"       <td>",
"        Hydrops in utero",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Teens-20s",
"       </td>",
"       <td>",
"        Mild skeletal dz with death in decades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Skeletal disease and soft tissue storage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        MPS VI",
"       </td>",
"       <td>",
"        Maroteaux-Lamy severe",
"       </td>",
"       <td rowspan=\"2\">",
"        N-acetylgalacto- samine-4-sulfatase (arylsulfatase B)&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Dermatan sulfate",
"       </td>",
"       <td>",
"        1-5 y",
"       </td>",
"       <td>",
"        Like MPS I without CNS disease, pachymeningitis cervicalis, death in teens and 20s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maroteaux-Lamy mild",
"       </td>",
"       <td>",
"        3-12",
"       </td>",
"       <td>",
"        Death in decades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Skeletal, cartilage, and ligament disease primarily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS IV A",
"       </td>",
"       <td>",
"        Morquio type A",
"       </td>",
"       <td>",
"        N-acetylgalactosamine-6-sulfatase",
"       </td>",
"       <td rowspan=\"2\">",
"        Keratan sulfate",
"       </td>",
"       <td rowspan=\"2\">",
"        1-5 y for severe forms",
"       </td>",
"       <td>",
"        Skeletal disease (similar to spondyloepiphysial dysplasia) with short stature, ligamentous laxity, corneal opacities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS IV B",
"       </td>",
"       <td>",
"        Morquio type B",
"       </td>",
"       <td>",
"        Beta-galactosidase",
"       </td>",
"       <td>",
"        Skeletal disease with short stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS IX",
"       </td>",
"       <td>",
"        Natowicz syndrome",
"       </td>",
"       <td>",
"        Hyaluronidase",
"       </td>",
"       <td>",
"        Hyaluronan",
"       </td>",
"       <td>",
"        Only one case reported",
"       </td>",
"       <td>",
"        Nodular synovium, popliteal cyst, large joint effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        CNS disease primarily, with less skeletal and soft tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS III A",
"       </td>",
"       <td>",
"        Sanfilippo A",
"       </td>",
"       <td>",
"        Sulfamidase",
"       </td>",
"       <td>",
"        Heparan sulfate",
"       </td>",
"       <td>",
"        2-6 y",
"       </td>",
"       <td>",
"        Aggressive behavior followed by progressive neurologic decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS III B",
"       </td>",
"       <td>",
"        Sanfilippo B",
"       </td>",
"       <td>",
"        &alpha;-N-acetylglucosaminidase",
"       </td>",
"       <td>",
"        Heparan sulfate",
"       </td>",
"       <td>",
"        2-6 y",
"       </td>",
"       <td>",
"        Aggressive behavior followed by progressive neurologic decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS III C",
"       </td>",
"       <td>",
"        Sanfilippo C",
"       </td>",
"       <td>",
"        GAC-acetylase",
"       </td>",
"       <td>",
"        Heparan sulfate",
"       </td>",
"       <td>",
"        2-6 y",
"       </td>",
"       <td>",
"        Aggressive behavior followed by progressive neurologic decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPS III D",
"       </td>",
"       <td>",
"        Sanfilippo D",
"       </td>",
"       <td>",
"        N-acetylglucosamine-6-sulfatase",
"       </td>",
"       <td>",
"        Heparan sulfate",
"       </td>",
"       <td>",
"        2-6 y",
"       </td>",
"       <td>",
"        Aggressive behavior followed by progressive neurologic decline",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35485=[""].join("\n");
var outline_f34_41_35485=null;
var title_f34_41_35486="Algorithm ileocolonic Crohns child";
var content_f34_41_35486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of ileocolonic Crohn's disease in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 483px; background-image: url(data:image/gif;base64,R0lGODlh1QHjAcQAAP///wAz/wAAAP+ZM4iIiLu7u0RERCIiImZmZpmZmd3d3TMzMxEREe7u7szMzFVVVXd3d6qqqh8fHz8/P7+/v5+fn29vb9/f309PTw8PD+/v78/Pz6+vr39/fwAAAAAAACH5BAAAAAAALAAAAADVAeMBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgUkBhIWGh4iJiouMjY6PkJGSk4SClpcxlJqbnJ2en4qYoqMolaROpqeqmKmrgwGusYGtskW0tbh2t7lAu7y/br7AO8LDxmbFIgUCOQIFScssDAQszkfJx9lgvgQCAgjRONbVzykJB94L5SjhKQ4MDeTtQtja9lvCBAYA8zXjNhEEJBCBgFqKfiYIQGjxj0i9exCt5NsXTcECbwgAWPS2cKOABwAMeDMQz5pIASSX/11k4ACAtQfeGJB4sJCEvm4KTqYUsLKlgYvfRjgACnKER2fREjDwRg0mzwYKvD0d6g1kNwEHWp54GLFrlIn8mD3IqIDlA5DvCjzYJ4LAgQYNFlBz5hau3GXPDGSke0CBCQMDbR54VjcuAbwhMxqgKMAvAAILTqwVgZSZgZqPF8STa1RABMhCWQKAUNQEV6+omYCNhk7qucCADwQGgCDj470FarcFx4w2bt0mxpbQR9A2Ad7FQ1KL6lgBzAWzAcimXCBagYsGHCCQ+s3BSYHOeSZIwP1AKVip00tEf4J4NOEjzgJw4Gxy27cNDswtUFh/ON18OUZCQAYVRNxj+PnXm/9uBizX2HDmxYdWZTMVpNkICETWgEAjuPWOVimcpt6IQ3CDUUVANeZRR0SFNFJJeb34H24uCiCTTUuhxB9bNe6UXIMaPfiYayQ4gM5F1VnmTVYAOCVQAUuhk8BVHFJpm2nskailalluyYKIXoaJA5gkkinmmTKYqZ6aaLb5ZZduksBmnHSWMCdqd9ZZZ55d8amnm6AEKuighG7y56EzFKrooowSiuijfPQG6aSUqiBppZhmemmmnEK6aaeg6vlpqKS2OWqpqHp5aqqpcufqq7DGKuustNZq66245qrrrrz26uuvvLJqxKrC5kFssToci2wdyi5rQ7POxgFttDJMS23/G9Ze60K22qbBbbeWgovHt+KeQG65Ypxb7gYYUOASABRgsAG6bbDrLjPxzkvvCxII0O+/+7bxr7/+BvxCBa5WYPAaCHOn8MIsaJCBVBloAHEaElNs8cUrWCCVBRyn4bE3IIeswgVSXWDyGSh7o/LKKUwgwAQwnyEzzTWjwIEAHORcxs49+3wCzkKPQXTRSCet9NKxDOD001BHLfXUVFdt9dVY/4n11lx37fXXYIctNtd2jG322VnrifbabLfttttlD6CG01rLTSnddeCNht508v2o33EATobgaBKutt10GB6G4mEyHqfjcyN+BuRaUl645HJYPkJDQJq7zhCaqxd6/0I8skFAdCUg9MPog2Melm3LKLYfCZ2bQCHorrfpdzeB8a7CgS/Uzo66N0SwwFgLCEhCNMCvnvsbgC8jQDzbXenS58KT0JAQrKO2O08iSPl76S1kb4LqR0S1Kvo9dC9G9CgR0AADC8h+fZNSGSTCUUkCoBRT+HuK+qbSIqdcyATu68ruDjCYCIhkIFdZQEuoRJHWDKRBBjjAdrwxHtcUwIIkaI15dBKPEUBAKg7wSEb0A4D5ReCDHFROBlUIAOOtJXnLaw0ziHNCb6QQKBkhD0b8l6OmpKOEI0ggGOB3juPoRTnXc4tfhGcfCl2mQxfizP48A5q2ZFF/JHAasMYIK/8kyIyMaFzgcR5AngTQpyUIyI41iMOAgURAJj9RXoagCIA61vBGyuhNYbRImQjEhywscQuC+mhHPOJQOGXRyulMMI2wPGYfnjmkRkQjAvI04Ipe3AwYAaDEL8BPAejwjv2cARzhTed61sGOdriDAO+4JjzQ2eAQEfi8JhAvBr/kwQKjIhOBnEMZsomQPgbojZwYhAA5GqGDuCOgGe1GMN/ID3cSML/rJICZjemcDjmEAuZYkjhuyeY4x5MiBVwHJbOUivVI2cs2nJI4TwQSX+DCQgnN53YiGAtkkLjHDc3GLQNVQSl7EMwXNFQHC2zSXNwogJas5Y1N2ocfRwCkqBj/EgIjrMlGUzc9BPFzlCKoI3wwdAB4MJJ2BlnpCirZjUuSQKXWO8BCAiIggR6Ql3E7n5ASA0VnxMVG/RSBkXhixSVZ1INREgiVBuIk1IlgoTx4KEOoENHNQTAdcExHBZfEx5Mw0H8chCFWSHDUEb5oBPM74lH8EhWDqFWa+2unCoR4kUvGVYDtvAo6cuLUAJIzifVkA1ahsNhkIUGrOGisAhO7Bsk2wbI3gOwKNGsDzN7Ds1YAbRJEOwPOpsC0NCDtMVQrBdYWwbUOfSxXKesm2D7BttyjrWyPgNoZ4DYXv2XC24Ybtir01nazJa5yl8tctsWtudCNmnF329roWve6/9h9WkSOiwXuak893hVWeKfLW/AyjTJ7GO+70qNeVLVXCup9r7HOu975lpe99JUvFOJr3vPq9wn8xa9/00td1Py3Uwf2ZYG9kmBNEfi+qWkwpiRsBHu9K19AsDC+5HUPDcOLw0mjsBEGBrAgkLhgEDmxBJYm4iI0TCoPA8KLvRFje8xYADUuWouJkDFvVEwIPRbAjyES5CGHOA8jE0DJhJDkJUOkyUzbMRFaJoCXCYHKVoYIlqOsh5sZwcuoATOL9QA0I5QZNWcec5fNqJ6jKU3K9I2zueTsgkbZmROggrOd7sznQl2hz4B+RJ65EOhCe+LPcIKDn0akZzklug+LJv/Go4Mx6Uc1egSRPkOmc7BpRA8aH5XWQ6dvMOoqlHq7hA51Hk5NA1ZLwdX2uLQIYO0FWsNg0ebzAftCpOo/yRoAts71Yz+3Z08zpJkqEPaz+mfJTPRaVKnea2vUUS3sodQfxGZItjH97Fc4dNswBUI4dn2eT2tBGAEJTEFwoOxqu7vc6/l2SIAY0PxF5RnHVCsBaDiCOxZpes4QoUpsBKIV2PoYvxYGTUqwIgQdCS4nKeYznEQNwbZEIBqcyREHzhJdKsDiLjkHAkR4cXADu9tI4IpJGPPxvijn3v4zTyUDikgQbcgB5/g4SG6HmCe24ODGSPikAVMC+aRFivNLwDL/kBgg5XxoNDsvTSgBcBeT0OjppHGJ1KWzkO052tjahiJzWrlva+R8qOskgVxy+YD9jHtB8+S1ubOg8Hm+EjAHms4JK8lK2zRIiGTdni6/YU2zl+d+DdAljeBt6m6bxEEtP2nIQyJz/ckURxlhgGgqEw9r/hzlcRJ6CghEEAIYnS5seeU/790fAjx9c8ROaCCTk8nXUwetm1n8VkBvhIdIxZlBUsBRGcDCCJoHSkyZ67+fAVLqtNXzb5o7FooBzZEUoOF5V7o8rzf84m/f61W15gY//v1neCTjXuc22OcA9GGI3hLtj34d4v+L9wuC/irAf8p5b6pow5//DgGAYqB//7hgf7MggPSgauT2BAtIgLVggFbQPAG4fsMjBAcige1ROg2IgGECgTDgdfpUDumXAhdIPiXCgb2ggL2FgTCwgdJHgR9ociPIAiW4fzDIP9EQR+FDVTExJDwxQSiEfH6EQbTkHq2xb0CxEEYoFUQEQMWGYP73F/RGHsXhcRgXR8fxeyYhI0zFSUGCEW7xcAGkGXiBcYXFVMbkUl2EJTD4AJEBS8ygg9IxJS73T3AkR+tQSUrxSThUgzPXJGjBADvSR9QQDaC0ey8YbyewGGGhAFToG/ejdSIQgtQxSIdhdTbBFkhXRwlVdaOkUy5RcTIxHar3hI1nAq9EIXIoG8ARc//IdExb5Bjh9EyaaADmtIOTOCW2+CCxBE9sCIWghgId1RiPCCAiWA6UeD3AcRzQZ1POyIq0FA6JV36NqA8RECGIqIgzMSH9o0hQQoeOgVEX9Q80BQ+d00V0ZHncmI5DUiG/yCkeOImQtwwKYBF7YUiRqE/4uE/5cYnJgUVtkXpT8lPh4ElURyPNNz+E9I5UcAtLhQ79g0o8MYQ9GEFA6ENCeEEG8Q7f4B5FhH37wFdKghUFN2souCXxKHYPIhL0kxHjNw5A8pIxghIN0IwcWRACaVjal1dLshdLUg4Q4FKM15CTRh/KgwwnqSUp6S3E1m4OyJCB5IRp8JSxsJRo0BD/AYFE2XiK85eUJGKVouaVPECVJ5iIXHl/YilpupCWAnZubImUMKhob2lgUXiAiGZoeFkIZkmUedmXgrYefmloezkFgVmYi3AJvxZ6DzgpiekmjRkFj2lfXCYLkTku+bWYnnKZlMmYmlmVnDlgm5mZoOmZojmZpGlpnekKlVkvp5Waq7CabIABElABG/Ndo6mabkIBPmYBWQabqoKZbdIvUjEBQeObKPmAaJScyrmczDkrNGOcSklnUSCc3kCc6HWb0rkEuilkvGmbppmdSyCbtIlc2AmeSKAvc1ae5rlfrrme7Kme7qlg8BmfSwCdX0mf8NWe+Fmf+rmfSWCfjOaf/wDWnwI6LARaoEQAoP21L83ZoA76oGgUYQajoNIioQFDoXCAoVagoa9ZKRxKBR96CiG6BiMKmROqBorXFtwhQelioQyaBiJRcSgxJEr4ES1KlxeKBlGBjYPVDTWKGV9Qou/5omcQEKUBE5/BHVvnBUI6oOvSLhcGYmKwoyPQowIAAd3whl3gYRgGEU0aCCpmBjE6JPvgoy4Sd1kQpqiGLjeWY2KQojTaQkthVVjQpl3xpYBQZLVZJ3p6p/sCZYgCqGuKLluGKIU6qOgiZoiiqF4aMGmGKI/aqAHjZovqogh6qeKAqZqaWfZgmJ4qKDXwqaLKZ1uAp7YwqqhKCaGaqv+sOiil2qlzGZar6iVkmZ7ZUKtloCa4Kge76p3H0KsDKIDA+gbDWl+/GqurJqzIKgrFaqoTqA26uqysIK2cKgvouZVLwILCeG0wUJIzwILRSgQLOAPtFpcgWgviuafqRwInRKclUK4tgE/cGm62Y3Iat6QqwDy1iK3OZgJUgRXzSoIayFntpq35+kuq06y1sJ0Z0J1fB1cMwIhFYLB/cW0zKBQoJAM1CJW31iVlYRz4GgPjKgMFa4IsMLIHy68bigvUOTNBc3IkoBTmlE48ARSGpE9AMRAZ2YQCcDrbJ68+WFHWsHRAQnIeZ3Gf1IMwEbILSRP0KE9h+BTrmihdsob/HMWFPTEaKLSE3sAPIIRB2OiDTEJyIadBf6eGWjpAOIkTBgQVUqEZIkSzC2CzXhtDPzFEImSK3QWhfNu3tIIzrXBFQCJFdUUb+6BPFVd5RPRJQNpJ0yOv9LEOusEgYASK1oB1D7B0RZICWfdELKGv9yF8IxWuNjFPlthz99ghGlWIzOBH/pZHRSIaWVelXVcURTsQpXiBg5EZotQZLyRIfVG4Oui6eMRyCUutW9Ky1mmSnSEV5nEgc3S4s3N2suhOspQAgSW9sKgMDGBODTKNQ2R4zqu1fzh6nLgA/ga6zzgbpNshYQuJt2FN6YQADbBMvNgYrgJ8MVse4BsUMFlx/wZwjcOxr7RBS7aUVoLEFtELTsDHHMcbLQzrsFPbRS4EvYQhvfdzTOWIRGMBijwFuZxzPPJokPXjEoZkexh7lOXbR90LTSDBPG+YfVObJh7LAEVheq3XjJy4uu04UnwUGiBCwosHJAo5SuioiT9VUE9SUhZsUz48jO5UUnpbLOm6lUmFAG2nwBdcVPh2fEtBkSQpWI0BtFTSEgGBjEjYkwU8xvIkPUERu1qZUS3EIdFwkzLMvK0GJ+/EE9RAQjPyV5pBHCJZt2tlPlZyfkNsEEEZx3bMI+EXVdx0EfqhxTZ1VyopfJI8xcJyrRxLBRRbA1jaA+0rpgFLmMhLJ8BaFv/4WJf9WqRSHIz7UqxfMMojIsuwest5TKunPCKcrMk/8MniFl60jAQLCMyzvMvqUcWdfAPqa8z0GoPUMQ+qEw7O7Mt1dso8dyobO3s3UM1jiczpEcFZBrNAsM0uAK/1ujzNgrJD2cpH8HYoYM6aBs7pobwvKwx+7AyH1bQQ8LRgyEBSS0LFiACANxuAlxFRqxlWmCSS7AAowhHSsSRcezpF1M4d6wOz60XXI3BdCCJqm9A1yQwNN3BZAXPHBLb4RG/8Jsr0fAfe0AEjsJ0vPQIdwB3uIgJn1LWbM5za8yqA+2in27Ml0LmZ59A7pIl9kXSWONA/XAKetIkDMQ6VYVH/mSsWgchs7DiJjbvMn+cD/qaDbQeHgZQX1qO7oruTRieIy0DVJj1CfXi4LAdJXqiWlloE9jzDJLCMyFECdzSQ6XvUAbmDes3U2YO9vyfDUo3Vg8EMd7eTl3SL/CBLFv0CmbYhDgQBSlFy8Ay/gb2+rAEbji1FZodXNgXFacfS6QHTRyDO1pzDo6J5H2fD5xTDAuna9VjChxg+OzXGOZlJYn2Q78GNmpvV7qiylP2WD1BH73AjnNdsrZgZnS0bwf1PzFbCHJJBfAS0zHF5qO0symzNPRLSkrEPBmVJjYyLJOQiLYlWhyXGH5eTMunGyfPQV9pCkuyRTGFW3orHVPvL/y5VwtwnyTa5FDi5g/S9EPLtF8aX3RjMHMrX3cvSyw97q8qqBuzMJQFjy10wzGRw4Uug4WRAqU0A4rDc31tC4jf6FS1NabN64ivOLKaMyyauJSgeBiJW49NX4S6e2qbcqj5+mHn840KuCRk+5EYerUee5I2wqTTgrCnO5Hbg5DauZsCJmm+WC1IOBlkemlWOKFt+mlxu5Ulz011+KF+OqWfOBWm+n1wqpdCmNGS+Cmpq5lS+Cnbq5XWuCn2K51cuC4JK530eC4cK6FBeB4zqa4VuB5GK6Ilu6JSy5qeg2o2eoHk+6UAA6aTwpdkFNpJ6ZHOw6V/T6Ugj4vakW6Nl6v9gbunVdQXBVaGqPlusjuq4+epT0OorYOtvgOmjQOqKJevP3D6+rgq6Lgqa/jxuvLsVCwS47gbDjgnFPjx+AQFa+uvCFOwiWuluQDj0CIgaQW9Fe4Y5q7U+tNJAdQ/NfgmSHjjGLhW22CQ150pdJ4omrEmRhALLji20Xuvr7ojdG9Gu8b0pOrRjjA70e9rlHmv5vuonsO3S3gAy9XclZd3MF7Y4xQL3zgbnvjDaLiSLMVcNgsgu8ZOADBV6dQIXT6LYXuo+cLEtcPJqkPGC8OwMZa8tb+2ZnvK9HuuirmOJY/O5tfNCE+dw4PJh5PPEnvBRQPSIBfRIrwSg7jVMnzP/Qg89T0825o7zN/+Znl7mjL71Yc7nXp/qhN703vLoZI/yWn/2Y9DmEu6YS5PuqjDnXY80MH8Cdz72PB8Le473QlP3J/Dnc180vC4Kgx74am80M5P2hz8Gi/7mi18Gg6+YShP5j18NWF/5lh/oP6DknA+qL3/5pNb5ot8JaJ80cA/hkILjKOD36aH6a1n6qu76XQn7li77dGD7vpr3KVgpuL85oG8DkcbyOeDMHk7Mq9L71xn2EH7s2/bJwl9t1GyyC7+CBDw+6ix3n6/5PpAKDD/t0PwD0e8Cxf8C3ixU2F/2cJ6AI7Dt8kFDKT1E/MPUZaxW0ZHR0B1wEg3QP9Xt/1IBAkUhAIgBAEcCPILAAIS7OLErOAXzrgZh3ASIH6BwcBEUCxckdjLeAImdgIACBALXLbfr/YLD4jFpbD6j0+o1u+1+w+PZ68hlULAQAAXDQTQ8CSg8nAAIFCSUISA4HF4xrETAXEmWnDxYHY6gEBwoNEBuPSygaJKYoKh04gE01pg0FjxaTTUYLOAROQEwWKE8PLQyFBD1FpEYNHHNxTU3lzlHS09TV1tTMx8rTOEd3ST8WSkIqpQiKiIkHFyNB7ECNAhEJE/VmHIWll/p36OmJCy6og6FkYEoxrES5AMfPoT7VgAwAO6OoGNFlhiogSLbtY5coHkMKXIkyTEUOv9mG4EHwoIGD/RcCbdHELBWphQoYeQIRSgvDyA5YDDJVINd/0QFi7WpUxFIq1C4YpFxJy8rBBjY8kWA1C5jv5IeKmYV5MsrHEtWA4l2Ldu2ztROS1kx4p0lLhTIROjgyBJZQBgs0CPDRQ5v67ZcLRrYXIMlB3Tpg3rkiAgSCviGAvLChgAanHHo4BHRV1AhREJXUcJkV6LOyFwc0IhFi9tpcGvjzq17y+1oZ3c3a/QOuJrfxNX0Pq58ObXkzYwzP1OnSnQ00KuDcY59O/cw2uFc7y6+TfjxhsyjTy+yvPr2XdiL/+5+Pv0w8Ourv89dPv7+9fX7Jx6A2PEXoIHVdID/UhYLMtiggw9CGKGEE1JYoYUXYphhg/0VeKCHbymooYgjkliiiSdGyOGHK4rUIYtnuPgicTHKWKMYNNroBY45urUjjz9O8CMcPgpZEpFFIpkkGUpWdySTTz7pJJTNTVmllTBeCZyUWc6XIJdfbPmlG2GKiR6ZL55ZZhppqrmfAF4C0MENQaIgpwt0AkBBEFfoGQUKfbpwUik3CGrIDXBOcOgViboAp50C4PkonoBCQylvQWCaqaabctqpp59mGiCbbZJaqjSjtoWqqauyipyorcIa61qqziqrrbdeQytauuLaazQR2LVABDwFoUx6vJKErK/LtjFCS405skNRR8hm/56yLTKb7XIICABRInpI28ABWKl3bUjmapsuGEto1AgpVLxQLXcbYHASCRRgsEF96Krb7xbceisELwKI2y16EgiAsML48euvv842AK0s0o7AwHDcVYBpBQw73PFawM4w7MBFQdCZeRpkcEMGGnDsscuyWnCDBSq+XDOrF9xwAc0280xqonju27PQanIgAAf+NTy00tsBHfTST0NtTdJRU63t1FW7jKLWW3M94o1Yg41N12OTXfaCX4ed9nO03Vre1WqrO+CXbsNdN3ls20q33Xtbh7esevMduH1+xwq44IcvQ3gXVNXGB0RugHJxGsl4YTjil5/lzQ0yyBJTIW8wbv8GAsbGc1g7N8BU8uNSFHKVACfIAFHshgpwgCygdL6F5Zcfbtwm5uQ2TlGcLDAMF/XAwwAgW0gkhcGcmJyCwQZfhQIEMOmuOG+8c+87NK5R/8QOmdmlhz8qjDBCIpUt0UcR3qyeAFepEBAQHTtxMxcfivnCyQG2z2N6KxAOACqROLRxD3HeuwJ1mCIWKWDFAGBxwPkSMAJfmMIv4IrEJDiBvRE0QAfDC8rjKLcQAEBAGS+wQwweg4AHJGIFBkOA6eCyuwTubYHAG8gPHGIIBZywWxX8nSEqg4JFnO4uMcEet76xh8ewIwiHcR8vZOG4VWxmerDRyDjeoz0G4lCBiiP/oiN4eAJjJGYhERAEU3Rgwe8ZsQQb9IL8UAAKkW2lMdiLAVfuCKwrlIUPEWAKJgwhw9UVsINm+WIpwti7McJRCus4zfh6sLkndgYSZIxjQKBQuy0ID4JRHMwNDADFIwKjf6oRQBOYwsBDcuF6XkSgI3PISDWc0BqjgxzB4oC7WXqnloGTGxhyWQ3H4YZywMyOMPlGzCzdsJlge+aVoinNqlHzGsbsjjWv+TJ9gSGb0jjhNrlARDecUw63fJs3lYQBCVSAZctMpi/KuYV0sgGfb+hmOzvWpwxYQGfZc4NmDFCUbh3gg7V7QQtYuYfytaZbt3CBHlbZBMOkr1uDic1V/3ACidO1xDAsmMHw1sDPfjoMYXM62kZuCYZORGwBmQjGPR1xgBMkIg976AM5AzGIpAzjdxcURg0gEAyWyBSU8vhdHgGQVDacFKW4AtWcWtoG+9WviOYsw0I2oTmJ1lMc5ICIRIRahoh+MgVccYBmuvW7JlL0brSUarp6o9I7sXQ2bYCpuDKRO4Jw1QqbKMsVlLkQhNREKb38XVCqBQFTWgEBpIjHG4vS1H2uk67+us0/A3rANhT0oH+1yGgsskpBtCYBhxWEReHhGCKScggHaEAjLLiDIyQAWuto6PNMmlnNqus274xn5VxKqqgCF1a3AecXxDkl5CaXVTFyLpSgG/9dU03XuG2y7nVJld1ecbe7avoursIrXjGRt22/Pe9UfWu298K3RHNlb6yyG9/74rdC86Vvq9gZDf+CiL+2AvAzXiVgWRE4Dgke0oERbOCdNVi6D25ZhCWMtAlXuFQLBh2GM9ymDauBXvbKU76c5mEN40dhCUsYhU/8YfxkLAgbM7GLx4sflKlMnvQBcY2Pw2M1xMwFM/MIcz3y4x7v5showJkLBFoNDVRAAhgYiZKRjJsqn+Fn1riABVImgEIZ2cplwrIZipbXaHCAUS6QQLLEjN4ANa0ZaqYqnens5i+R2S1pDgKb76y0PNeGy14Gs59t9rYBIDrRil40oxvt6Ef/QzrRXYCylAsttENHOtOa3nSjwVBkS78M08pBNKirJurjkLrUUTs1cVKt6qexGjiufvWfdTPr3dya1j2LdRp0QY1c69rQth4AmC7ZBV9PA9jBDvWwwRSJXnIB2dJQ9rI9xutXxgAGqxTMCeDag/JBEAkj7UxJuUDtajvs2oPqjCwC2QdkSzYiE1QmH/n3hXOju1/qNmRQhvXViWQbNqU1ZAEwQsEg7HEL+M53XZutIw46gLANkQcK16HGueThsmBYOMOzte/nrcIubDyBZv4XkUuWvAa8ReQVON7xZe2boP1rg8tf3quYg3bmbKi5zW+F87bwvOcOzk3QRVJ0offX/+GtJjbSNztsTkM96o5uutOJLvWrY53q+u6w1sMG6P12HWtfD2bY4TZ2ZpZdbWcHU9rVzvW2Q23tOoK7199O91pf+O6mtrved833vgs774CH9d8H77IC1Tnxil884xv/KcPLCPHthTyLJO9zylceDXJPMuZXZPkBd/5Dnx966A00+t2ArDMig5dDZ1T6A50+NxCT2MikJ68rv970mj8OwFDwrZGJi1xayn3hwUgcdkHFZPCi4vCJD2EviPg8+Pp0W3rvPHARDLe6if69Sux893xHxQvTzez7MrKKSY4t4mfx98E/hhjfYMa6Sb2wiEWy6OEG/i6Qf/uPNQYcu8DKtP8KAAqAAPZfuZhBkAnAkLWKAjLgAZqJGTCZADjZzeQMBCKgGWiZrGwgBkZgmRmNrZiZB/pfluFKnJHgfqQgkm3eCkJTfsGghCRODNJgDWJI09lgDvqNDvJgD54N0lEXd5xFELIKEfaYEVbHEGpXtiChizUhcyhhzzyhh02hckQhz1RhhWUhcVyhzWxhg2Vh6FSDtBXXZ0VDHYzWGR6JPonBZVCHOuGg9kyH7XiBPfFGGsLBUrTO54TTDi7hybkATXXBU5mBHYIBG3pHHCEiGDyWb/yhqkGHSqDQ/CAHHjaDLpDhPOkVGhhARTGAyHCB8ZyBIX7BIoaBWa1BITnDFx7/WCRWRE14Ug9kgl2swGmdwxEJxg0UhgusjlEhxgKoBOp0Al+U20AZ4yjqQVRs1MHVzrY5gQywQkTZlmhEEUltgi0CokFl1PpglGu4z0IJwQxsQUQBkR0clDok3ODEYSmWEh6EQiUsRAPtViEcQk7JUSw8AgdtQSWgAiboof98Qk9oIoBohjE0FgoFgyO4mx/QIfP4gjHUQheMQwQMFleExWw1BgEMVRGZlQYZQmR5wjj81ULwVVIJgCCeASsKmCtug8UkkUL4lSQdRRHZ4yIYxEy4wxXEwzxAQD38o1FEhhlaFSciQGM0AVqtg00FAcBxwWolxDuw1Td4FUQcAlYh/8AmoaIcaZUuMM5CWKVWpYFK8hdLTiIorE48ysJAJNZN5AQ+8gTL/QJQCIVFbAVDzORA/mEn7lQCHCQDtdsekaEyoZHwlcBkuRUJrCUxYORjYOViocNW0uNIWsVixmRYPmKpkSVdeJLFxeRA7IVr+MULLAYp7WJaxQS5LMYmlMYQ5ANcbuIiTQ5MpE9sadVp4QUf+h4vhoZANsVCvVErTIYjhNYm6dZb6YEjcKVkokBogWXfrKOMdKF6EJB5iCV9VWdtROd4TIfOcdNlgtp1ukV2Zo13Whp4toV4eox5dhd7mGJuiKFQvuYYuCF3JpklApYZtCccAqFL5Sc6lUF7pv/Tex7jUJpBI66JfZqBA9jFKWUHghoBfpJAJq4ieRYae6JKfzaoGKDnF6ii5iFoGzIATBAASuoIgl4GhIaEel7Xb9jiJlTQZ/jBDNSAJyWBXbSSD0jRNdpFMAynZYhcAShoIOLlR6BjLErjIXTLDbTEuIXoDeCFjBrSTTkCCMUEJR6D+gyGZ4DPCgwjuQkEFcycJ0XoCZQMYcRiCThRmeKAMw6ozf3GKJiDi7amW0YFKngFCwCVYsoCKhJCTGCkTA1WZNZlc/nhR9DUO8JAV73hQcjDUwBPnZ7ASeKiVi7RVlkBpH5kC7VQQJaQsWyBMfwjxb1lIv0LKYiqTvFBtaj/aHT9Bj8YUQXdpEEYgQ/NpEToAipGhlVOpTkMQmewXHY6wksCkWCVQVTyov3s0GE86E7oAK1qak35nrImZVpOUmvSgcFFER78YycIQSO4g+t8ErcW5b+16cu9KVgYURsBxU5ERZ/eaWLeqmNKhZ9GDGMiJrr66ZDe4agWFrEekWGCgycw0LC0a6Tmzi2QKB/Q1IgyFg7MaxlVayqwnMRVhQ0YxVsK5ERW3KcmAMWWa8f9xmdSxjViBpfqYpbOKJi2li4Up48KaY8CJ2iS0q8W6r6+j8ApKkHclsEUJJqyEZRSxRqlYcHNgEZCA8pqlRlJbGFt0TjOwJiCgjWKVMnNdhYVtIRtfizDXcd00seGooWEfsiqJtdvbGd/eC1JCBKPiC1wre1InG2/tC1dxW2K1qwXUqifza1HvG3c3O2d5a2CwOd4xqEP5tcMEu7hwuDgIi58Ge7iOq7ZuGDkSu7kUm7lWu7lYm7mau7mcm7neu7ngm51hAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AZA: azathioprine; 6MP: 6-mercaptopurine.",
"     <br/>",
"     Dashed line indicates less preferred option as compared with solid line.",
"     <br/>",
"     * For patients with severe disease, enteral nutrition therapy might be used in combination with glucocorticoids or other medical treatments for induction of remission.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Although aminosalicylates are attractive because of low toxicity, it is unclear if these drugs are superior to placebo in preventing relapse. As a result, thiopurines are increasingly used for maintenance therapy, especially for patients with severe disease.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Athos Bousvaros.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35486=[""].join("\n");
var outline_f34_41_35486=null;
var title_f34_41_35487="Fusarium infection hard palate";
var content_f34_41_35487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusarium infection hard palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Black necrotic hard palate caused by Fusarium species in a 29-year-old patient with leukemia and fusarial sinusitis and pneumonia. The infection later became disseminated and involved multiple organs, including the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright &copy; 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_41_35487=[""].join("\n");
var outline_f34_41_35487=null;
